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Abstract 
 
People with Chronic Kidney Disease (CKD), advanced age and systemic cortisol 
excess demonstrate skin specific similarities including poor wound healing.  There is 
accumulating evidence that patients with advanced kidney disease age prematurely. 
Studies have demonstrated the cortisol producing 11b-Hydroxysteroid 
Dehydrogenase Type 1 (11b-HSD-1) enzyme activity is increased in aged skin. We 
hypothesized the same should be true in the uraemic state. Skin specific 11b-HSD-1 
and therefore cortisol excess may be the unifying cause for the skin phenotype and 
poor healing seen in CKD, advanced age and systemic cortisol excess. 
 
The aims of this thesis were to investigate the presence of 11b-HSD-1 and 11b-HSD-
2 within rodent skin with and without uraemia as well as determining the activity of 
11b-HSD-1 and to elucidate the role it may play in wound healing. Finally, the 
efficacy of an 11b-HSD-1 inhibitor in healing was assessed as a potential future 
therapeutic target. 
 
In vitro studies which included Lactate Dehydrogenase (LDH), cell viability, scratch 
assays and cortisol Enzyme Linked Immunosorbent Assay (ELISA) were conducted 
using 2 different types of primary skin cultures with the uraemic toxins Indoxyl 
Sulphate (IS) or p-Cresol (PC) or the specific 11b-HSD-1 inhibitor emodin. An in 
vivo model of skin wounding was developed in male Wistar rats rendered uraemic by 
an adenine supplemented diet. Healing was measured in uraemic and non-uraemic 
control rats at baseline, with the application of topical emodin or with systemic 
emodin administration. Skin samples were processed ex vivo to extract protein for use 
in immunoblotting or Ribonucleic Acid (RNA) for Polymerase Chain Reaction (PCR) 
and a wound healing PCR array. Immunohistochemistry was completed for selected 
skin samples as were corticosterone (cortisol equivalent in rats) ELISA. 
 
The presence of 11b-HSD-1 and 11b-HSD-2 in Human Dermal Fibroblasts (HDF) 
and Human Epidermal Keratinocytes (HEK) was confirmed by western blotting. No 
differences in LDH activity, cell viability or cortisol production with the 
administration of IS, PC or emodin could be detected. Scratch assays utilising uraemic 
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toxins in isolation did not demonstrate a significant delay in wound healing. An 
improvement in healing using emodin in isolation could also not be demonstrated. 
 
Contrary to the in vitro exposure to solitary uraemic toxins, the in vivo findings 
consistently demonstrated a delay in wound healing in uraemia and the beneficial 
effect of emodin on healing when administered systemically. This could not be 
attributed to changes in 11b-HSD-1 or 11b-HSD-2 Messenger RNA (mRNA), protein 
expression or enzyme activity with the techniques employed. To elucidate a definitive 
role of 11b-HSD-1 would require the use of radioactive isotopic activity assay and 
the use of a skin specific 11b-HSD-1 Knock-Out (KO) mouse model. It would be 
most useful to reproduce this work in human skin, comparing uraemic patients to 
healthy live kidney donors. 
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1.1 Uraemia and Ageing 
The uraemic syndrome is a term used to describe not only the accumulation of 
nitrogenous waste products in the plasma and its’ concomitant symptomatology but a 
series of pathophysiological changes which occur in the body secondary to renal 
failure (1). Considerable work is ongoing in many fields to determine how these 
changes are mediated and whether they can be reversed without adverse consequence 
by restoration of normal renal function after kidney transplantation. As donor kidneys 
are a finite resource, reversing these changes or limiting unfavourable sequelae with 
alternative methods has become increasingly important. 
 
Patients with CKD have been observed to suffer a multitude of complications, with 
damage occurring in multiple organs including kidneys, bone, muscles, brain, heart 
and vasculature (2). The most frequently encountered clinically are cardiovascular in 
nature including coronary artery disease, congestive heart failure, peripheral arterial 
disease, stroke and arrhythmia (3). Furthermore, clinicians note that patients with 
CKD are biologically older compared to age-matched non-uraemic controls (4). It has 
been postulated that uraemia accelerates the process of ageing via a multitude of 
processes including telomere loss (5), accumulation of advanced glycation end 
products and increased oxidative stress (6). Additionally, patients with CKD have 
been noted to be inflamed with dysregulated immunity (7) and altered autophagy (8), 
all of which may propagate such cardiovascular and other organ abnormalities in the 
CKD population. 
 
1.2 The Structure of Mammalian Skin 
Skin has numerous functions in humans including a barrier function, protecting 
underlying tissues and organs as well as defending against pathogens, 
thermoregulation, electrolyte and water content regulation, insulation and the 
production and inactivation of different substances such as vitamin D (9). It can be 
considered in 3 main layers, each of which has a different structure and cell 
composition. These are the epidermis, dermis and hypodermis (9). 
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Figure 1.1 Epidermal structure. Republished with permission of McGraw-Hill 
Education from Junqueira’s Basic Histology: Text and Atlas, 12th Edition, Mescher 
A, 2009 (10); permission conveyed through Copyright Clearance Center, Inc. 
 
 
1.2.1 The Epidermis 
The epidermal layer consists of five sublayers; stratum corneum, lucidum, 
granulosum, spinosum and basale (from outer surface to inner) which together 
provide more barrier protection than a monolayer of epidermal cells (Figure 1.1) (11). 
The principal cells present here are keratinocytes, the remaining are melanocytes, 
Merkel and Langerhans cells (11). The epidermis contains no blood vessels; instead 
it gains its nutrient supply from dermal diffusion (12). Obtaining oxygen via the 
atmosphere has also been shown to be integral to epidermal cell growth and 
differentiation (13). A single layer of keratinocytes in the basal layer undergo a 
programmed process of differentiation. After mitosis, some daughter cells migrate 
into the upper epidermal layers, the rest remain in the basal layer.  During transition 
to the upper layers, the keratinocytes change morphology, for example in the 
spinosum layer they are spindle shaped due to the formation of desmosomes with 
adjacent cells, as well as initiating the synthesis of various structural and catalytic 
proteins (14). Above the spinosum layer is the granular layer, here keratinocytes 
contain keratohyalin which is needed to organise keratin filaments in the upper layers. 
Cells here start to lose their nuclei and cytoplasmic organelles (11). The stratum 
lucidum is a zone where cells transition from being live to dead and keratinized. Cell 
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organelles are destroyed, granules fuse with plasma membranes releasing lipids into 
the extracellular space (15). In the final steps of differentiation, keratinocytes are 
transformed into anucleated, flattened corneocytes, with aligned keratin filaments, 
surrounded by an inner envelope of cross-linked proteins and outer envelope of lipid 
thus forming an effective barrier (16). 
 
1.2.2 The Dermis 
The dermis has 2 sublayers; a papillary layer (near the epidermis) consisting of loose 
connective tissue with finger like projections to interdigitate with the epidermis and 
a reticular layer near the hypodermis with dense irregular connective tissue (collagen, 
elastin, reticular fibres) which confers strength and elasticity (11). The dermis 
contains adnexal structures such as sweat glands and sebaceous glands as well as hair 
follicles, nerve endings, lymphatics and blood vasculature (9, 11). 
 
1.2.3 The Hypodermis 
The hypodermis attaches the overlying skin to bone or muscle underneath. It contains 
its own blood vessels and nerve endings as well as loose connective tissue, elastin and 
adipose (to provide insulation) (9). 
 
1.3 Skin Abnormalities in Chronic Kidney Disease 
Patients with CKD develop a multitude of skin changes associated with the duration 
and severity of their renal failure (17). A spectrum of skin colouration has been noted 
in CKD; pallor secondary to anaemia of chronic disease or relative erythropoietin 
deficiency, yellow due to the retention of fat soluble pigments within the dermis and 
subcutaneous tissues, grey-brown discolouration due to haemosiderin deposition as 
well as hyperchromia after dialysis initiation (18). Skin is often xerotic and scaly with 
a tendency to decreased sweating. Shunting of blood away from cutaneous beds, 
likely due to autonomic neuropathy, leads to atrophy of sebaceous glands and sweat 
glands, resulting in reduced skin turgor (19). These changes also adversely affect the 
elasticity of the skin, causing it to be weak and susceptible to damage (20). 
Precipitation of crystals of urea on the skin surface, termed ‘uraemic frost’ can 
infrequently be seen (21). More commonly, skin is noted to bruise easily. Platelet 
defects in uraemia have been extensively studied in the context of systemic bleeding 
diatheses (22). It has been postulated that the build-up of guanidinosuccinic acid 
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inhibits adenine diphosphate induced platelet aggregation which leads to bleeding and 
hence ecchymoses formation (23, 24). 
 
1.3.1 Calciphylaxis 
In addition to these widespread changes, skin disorders specific (although not 
exclusive) to renal disease can develop. Calciphylaxis or calcific uraemic 
arteriolopathy mostly occurs in patients with advanced CKD treated by dialysis (25) 
although cases have been reported in alcoholic liver disease, malignancy and 
connective tissue diseases (26). Small vessel mural (predominantly medial layer) 
calcification, micro thrombosis and fibrointimal hyperplasia of small dermal and 
subcutaneous arterioles causes ischaemia and septal panniculitis (27). Painful skin 
lesions, with resultant skin necrosis, non-healing ulcers and gangrene can also 
develop (28). Risk factors for these events are thought to include Caucasian race, 
female gender, abnormal bone mineral metabolism (increased calcium phosphate 
product), hyperparathyroidism, hypoalbuminemia and the use of medications such as 
warfarin (29).  It is associated with considerable morbidity including severe pain, 
infections and non-healing wounds as well as high mortality rates (29). 
 
1.3.2 Nephrogenic Systemic Fibrosis 
Nephrogenic systemic fibrosis has been associated with exposure to gadolinium based 
magnetic resonance imaging (30). It has been postulated that the process of 
transmetallation occurs, whereby cations such as calcium or zinc are substituted for 
the gadolinium ion (GD3+) in chelates, thus releasing free GD3+ that can attract 
fibrocytes via the release of several cytokines ultimately inducing fibrosis (31). It 
predominantly presents as thick, hardened and indurated skin of the extremities, with 
the potential for contracture formation and hence reduced mobility, although internal 
organs such as the pleura and myocardium can also be affected (32). Susceptibility to 
breaks in the epidermis due to pruritus predisposes to ulcer formation and superadded 
bacterial infection (19). Histologically, thickened collagen bundles with mucin 
deposition, proliferation of dermal fibroblasts and elastic fibres, without signs of 
inflammation is observed (32). 
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1.3.3 Uraemic Pruritus 
Uraemic pruritus is frequently encountered in patients with advanced CKD (33).  
Despite this, the pathophysiology is still not well understood (34). Two popular 
hypotheses currently exist; the opioid hypothesis (overexpression of opioid µ 
receptors and down regulation of k receptors in dermal cells and lymphocytes) (35, 
36) or the inflammatory supposition with the accumulation of chemical transmitters 
such as pentapeptide enkephalins, proteases, serotonin and histamine as well as 
undefined ‘uraemic toxins’ (21). The most common skin presentation of pruritus is 
xerosis although skin can appear normal (34). Itching leads to defects in skin integrity, 
such that excoriations may become ulcerated (21).  Lichen simplex or prurigo 
nodularis may also manifest (37). Histologically, the commonest features are of a 
microangiopathy with endothelial cell activation and thickening and reduplication of 
the Basement Membrane (BM) (17). 
 
1.3.4 Wound Healing in Uraemia  
In addition, causative comorbidities such as peripheral vascular disease and diabetes 
mellitus directly impact on wound healing. In clinical practice, poor wound healing 
contributes to prolonged hospital stays, a susceptibility to infective complications and 
significant morbidity, including a considerable negative psychological impact (19, 
38). The skin phenotype in patients with CKD are akin to those noted in the elderly 
population (39) further supporting theories of accelerated ageing in uraemia. This 
phenotype also has many similarities to patients diagnosed with Cushing’s syndrome. 
In this condition, systemic cortisol excess has been observed to cause identical 
dermatological changes as seen in CKD patients, as well as hypertension, 
hyperglycaemia, cognitive deterioration, mood changes and chronic fatigue (40, 41). 
It is quite possible that, at least on the tissue specific level, hypercortisolaemia is the 
predominant influence in ageing, Cushing’s syndrome and uraemia. 
 
1.4 Steroid Production in the Skin 
1.4.1 The Mevalonate Pathway in the Skin 
It has been recognised that the skin is an important extra-adrenal steroidogenic organ, 
containing the apparatus necessary for producing Glucocorticoids (GC), androgens 
and oestrogens from systemic precursors or through the local conversion of 
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cholesterol to desired products (42, 43). The building block of all steroid hormones is 
cholesterol which is produced in eukaryotic cells from acetate by the mevalonate 
pathway (described in detail in Figure 1.2 (44)). 
 
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, commonly known 
as the statins, prevent the formation of mevalonate at a rate-limiting step in the 
cholesterol synthesis pathway (44). Although statins are prescribed predominantly to 
lower plasma cholesterol and modify cardiovascular risk (45) studies have also shown 
augmentation of wound healing when administered topically as well as systemically 
(46, 47). The beneficial effects have been linked to various factors such as increased 
angiogenesis promoted by greater Vascular Endothelial Growth Factor (VEGF) 
expression (48), increased Nitric Oxide (NO) concentrations (48) and lower 
expression of Tumour Necrosis Factor-Alpha (TNF-a) and Interleukin-1b (IL-1b) 
(49). In addition, improved hydroxyproline content and collagen thickness have been 
observed (48). At present, no published studies have correlated the enhanced healing 
with statin treatment to a reduction in skin cholesterol and hence reduced local 
steroidogenesis. 
 
It is interesting to observe that an intermediate in the mevalonate pathway, Farnesyl 
Pyrophosphate (FPP), can act as an agonist for some nuclear hormone receptors (50). 
Vukelic et al. showed that FPP can act as a ligand at the Glucocorticoid Receptor 
(GR) ex vivo and in vivo inhibiting keratinocyte migration, epithelialization and 
subsequently wound healing (51). This effect was ascribed to activation of the GR 
rather than enhanced protein farnesylation by using an inhibitor of the farnesylation 
process. 
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Figure 1.2 Mevalonate pathway describing the production of cholesterol from 
acetate. coA: co enzyme A, HMG: β-Hydroxy β-methylglutaryl, PP: pyrophosphate, 
IPP: isopentenyl pyrophosphate, GGTI: geranylgeranyl transferase inhibitors, FT1: 
farnesyl transferase inhibitors. Adapted from Buhaescu and Izzedine 2007 (44). 
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1.4.2 Steroid Hormones in the Skin 
Skin expresses Steroidogenic Acute Regulatory Protein (StAR) and StAR-related 
lipid transfer protein (STARD3) (52). StAR is a 30 kDa protein that mediates the rate 
limiting step in steroid biosynthesis by transferring cholesterol from the Outer 
Mitochondrial Membrane (OMM) to the Inner Mitochondrial Membrane (IMM) (53). 
StAR has been detected in epidermal keratinocytes, sebocytes and outer root sheaths 
of hair follicles as well as regulators of StAR being identified in the epidermis (42, 
43). 
 
Synthesis of all steroid hormones proceeds with the production of pregnenolone from 
the cleavage of a side chain of cholesterol by the cytochrome P450 enzyme 
CYP11A1. Pregnenolone is successively modified by a specific series of 
steroidogenic enzymes to produce either mineralocorticoids, GC or sex hormones 
(oestrogens and androgens). This is illustrated in Figure 1.3. The enzymes expressed 
in human skin involved in the production of GC are CYP17A1 which converts 
pregnenolone to 17a-hydroxypregnenolone, followed by the actions of 3b-HSD-2 to 
convert this to 17a-hydroxyprogesterone. CYP21A2 then acts to form 11-
deoxycortisol which is finally converted to cortisol by the enzyme CYP11B1 (42, 54-
56). 
 
Glucocorticosteroidogenic activity has been identified in epidermal keratinocytes (55, 
57, 58) melanocytes (59) and dermal fibroblasts (60-62).  In addition, skin cells 
express enzymes to locally regulate the activation or inactivation of GC (discussed in 
section 1.4.4). 
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Figure 1.3 Steroidogenic pathways in human skin. Cholesterol is transferred from 
the OMM to IMM where it then has its side chain cleaved by CYP11A1 to produce 
pregnenolone which is then metabolized by steroidogenic enzymes to form 
mineralocorticoids, GC or sex steroids. Adapted from Slominski et al. 2014 (43). 
 
 
1.4.3 GC Regulation in Skin 
GC synthesis is systemically regulated by the Hypothalamic-Pituitary-Adrenal (HPA) 
axis (9, 40, 63). The hypothalamus produces and releases Corticotrophin Releasing 
Hormone (CRH) which stimulates CRH Receptor-1 (CRH-R1) in the anterior 
pituitary. Consequently, the anterior pituitary produces and releases the 
Proopiomelanocortin (POMC) peptides; Adrenocorticotrophic Hormone (ACTH) and 
b-Endorphin (b-END). Upon ACTH release into the systemic circulation, 
Melanocortin Receptor type 2 (MC2R) of the adrenal gland are activated resulting in 
the production and secretion of corticosterone (in rodents) or cortisol (in humans) (59, 
64). Cortisol is 90% bound to corticosteroid binding globulin, whereas 4% is free. 
The remaining 6% is bound with a low affinity to albumin (40). Various factors such 
as infection, inflammation and trauma can affect the HPA axis at all levels of 
production as well as negative feedback from the produced steroid products 
themselves (63). 
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CRH, the CRH receptors CRH-R1, CRH-R2, POMC, POMC-derived peptides and 
associated processing machinery as well as steroidogenic enzymes have all been 
described within the skin itself (54, 60, 65-67). It has been shown that cell type-
specific, functional regulatory loops exist with regulatory feedback pathways similar 
to those seen in the central HPA axis operating at a peripheral level (67). In addition, 
it has been postulated that local (skin) to central cross-talk can occur. Skobowiat et 
al. demonstrated that skin-only exposure to Ultraviolet B (UVB) radiation stimulated 
cutaneous expression of CRH, Urocortin (Ucn), POMC, ACTH, b-END, CYP11A1 
and 3b-HSD peptides and MC2R and StAR genes with the final steroid product 
corticosterone being produced at significantly higher concentrations compared to 
animals not exposed to UVB. Moreover, hypothalamic CRH gene expression and 
peptide production was increased, as well as adrenal MC2R mRNA, StAR mRNA, 
CYP11B1 mRNA and plasma CRH, Ucn, ACTH, b-END and corticosterone. 
Changes in plasma concentrations required an intact pituitary gland to occur (64).  
The mechanisms of this central activation are currently not well-defined but may 
include neural or humoral pathways including the promotion of cytokine production 
by UVB (64).  The skin has a prime peripheral location with exposure to a variety of 
environmental stressors such that future research will be challenging. 
 
1.4.4 The GR 
GC exert their actions via the GR which is a ligand-dependent transcription factor. 
Although only one gene is found on chromosome 5q31-32, 10 exons codes for the 
GR and it is expressed as two main isoforms GRa and GRb, due to alternate splicing 
of exon 9. Both isoforms are expressed in all organs and tissues including skin (68). 
Thus far, GRb has not been reported to bind GC and hence is transcriptionally inactive 
(69). Interestingly, Oakley et al. noted that when culturing cells to overexpress GRb, 
a dominant negative inhibitory effect on GRa mediated transactivation was observed 
(69). Varying expressions of the a and b isoforms have been studied in cases of GC 
resistance (66) and could also be implicated in regulating specific tissues’ sensitivity 
to GC.  
 
Lu and Cidlowski demonstrated that a single GRa mRNA species generated 8 N-
terminal GR isoforms via alternative initiation sites (named GRa A, B, C1-3 and D1-
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3). Each of these GR isoforms has unique tissue distribution patterns. They found 189 
genes were regulated by all GRa isoforms, however the total number of genes 
regulated by individual isoforms varied, indicating each isoform regulates a unique 
set of genes (68). They postulated that in the same cell, the N terminal isoforms could 
homo-dimerize, hetero-dimerize or compete for co-regulators. They could also 
preferentially interact with different transcription factors or response elements on the 
same genes as well as undergoing post-translational modifications, thus further 
expanding the potential diversity in expression profiles (68). 
 
1.4.5 Pre-Receptor Regulation - The 11b-Hydroxysteroid Dehydrogenases 
The production of active GC is regulated by the 11β-hydroxysteroid dehydrogenases. 
These are microsomal enzymes of the short-chain alcohol dehydrogenase superfamily 
(70). Two isoforms 11β-HSD-1 and 11β-HSD-2 have been characterized in human 
tissues. 
 
1.4.5.1 11b-HSD-1 
11β-HSD-1 is a 34 kDa protein initially purified by Carl Monder’s group from rodent 
liver in the 1980s (71). Since then it has been identified in many other organs 
including adipose tissue (72), skin (73), vascular smooth muscle (74), heart (75), bone 
(76) and placenta (77) in addition to the adrenal cortex (72). In humans, expression is 
absent in the first 3 post-natal months, after which expression rises in the next 9 
months to adult levels (40). The gene is localized to chromosome 1q32.2 (78). 11β-
HSD-1 is found anchored to the Endoplasmic Reticulum (ER) membrane orientated 
such that its catalytic domain is within the ER lumen (79). It is a Nicotinamide 
Adenine Dinucleotide Phosphate (NADPH) dependent enzyme under complex 
regulatory control by substances including GC, growth hormone, cytokines and stress 
(80). 
 
The type 1 isoform is bi-directional; oxoreductase activity has been shown to 
predominate when previously studied in intact cells such as hepatocytes, fibroblasts, 
lung and adipose stromal cells (80). This is the conversion of inactive cortisone to 
active cortisol (in rodents; 11-dehydrocorticosterone to corticosterone).  However, 
oxoreductase activity is unstable and upon tissue homogenisation can be lost, 
 
31 
enabling dehydrogenase activity to predominate (81). The directionality of the 
enzyme is thought to be determined by the position of 11β-HSD-1 within the ER 
lumen where Hexose-6-Phosphate Dehydrogenase (H6PDH) is located. H6PDH 
maintains a high enough NADPH concentration within the lumen to permit 
conversion of cortisone to cortisol (Figure 1.4). Clinically, loss of function mutations 
in the 11β-HSD-1 gene cause ‘true’ Cortisone Reductase Deficiency (CRD) which 
presents with premature adrenarche in children or polycystic ovary syndrome 
secondary to hyperandrogenism.  In response to the reduced cortisol concentrations, 
the HPA axis will be activated promoting ACTH-mediated adrenal GC and androgen 
secretion. Urinary steroid profiles reveal elevated cortisone metabolites but low 
cortisol metabolites (82). Loss of function mutations in the H6PDH gene causes 
‘Apparent’ CRD (ACRD). In ACRD, NADPH/NADP+ ratios will be reduced, 
favouring the dehydrogenase activity of 11β-HSD-1, hence inactivating cortisol to 
cortisone (83, 84). 
 
1.4.5.2 11b-HSD-2 
11β-HSD-2 is a 44 kDa protein with the human gene located on chromosome 16q22 
(78). This isoform is found largely in classical aldosterone target tissues such as the 
distal nephron of the kidney, colonic epithelium and salivary and sweat glands as well 
as adrenal cortex (85). Unlike its counterpart, it is widely expressed in the foetus and 
placenta from early to mid-gestation (86). It has Nicotinamide Adenine (NAD) 
dependent dehydrogenase activity, catalysing the opposite reaction to 11β-HSD-1 
inactivating cortisol to cortisone (in rodents; corticosterone to 11-
dehydrocorticosterone). It is anchored in the ER membrane with its catalytic domain 
orientated within the cytoplasm (in contrast to 11β-HSD-1) where it may physically 
interact with the cytoplasmic Mineralocorticoid Receptor (MR) (Figure 1.4) (79, 87). 
The type 2 isoform is unidirectional, only demonstrating dehydrogenase activity. 
Clinically, loss of function mutations in the 11β-HSD-2 gene results in the syndrome 
of apparent mineralocorticoid excess. As 11β-HSD-2 is unable to convert cortisol to 
cortisone, more cortisol is available to bind to not only the GR but also the MR which 
has a similar affinity for corticosterone, cortisol and aldosterone (78). Affected 
patients usually present in childhood (although few adult cases have been noted) with 
severe hypertension, sodium retention, hypokalaemia, metabolic alkalosis and low 
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plasma renin activity. Suppressing endogenous cortisol with dexamethasone was 
noted to reverse the features of mineralocorticoid excess (88). 
 
 
 
Figure 1.4 Diagrammatic representation of the reactions catalysed by 11β-HSD. 
G6P (Glucose-6-Phosphate) is transported from the cytoplasm into the ER lumen by 
a G6P transporter (G6PT) where H6PDH oxidises it to 6PG (6-Phosphogluconate) 
and concurrently reduces NADP+ to NADPH, which is available for 11β-HSD-1 to 
convert cortisone to cortisol. 11β-HSD-2 catalyses the reverse reaction, inactivating 
cortisol to cortisone. Its presence allows only aldosterone to bind to the MR. Modified 
from Gathercole et al. 2013 (40) and Draper and Stewart 2005 (85). 
 
 
1.4.5.3 11b-HSDs in Uraemia 
Our group has previously shown that 11β-HSD-1 mRNA, protein and activity is 
upregulated in the uraemic liver with resultant elevation of intrahepatic GC 
concentrations, without systemic GC excess. The subsequent increase in 
gluconeogenesis contributes to an insulin resistant state which can be ameliorated by 
inhibition of this enzyme (89). The mechanism of this elevated intrahepatic 11β-HSD-
1 is currently unclear. The uraemic milieu may promote similar upregulation in other 
tissues with a multitude of adverse effects. 
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N’Gankam et al. observed that patients treated by haemodialysis had signs and 
symptoms such as abnormal body fat distribution and osteopenia which could be 
attributed to an augmented GC response. As the kidneys are important for GC 
excretion and metabolism they analysed the concentrations of various GC related 
molecules via gas-chromatography mass spectrometry. They found that mean plasma 
concentrations of GC metabolites Tetrahydrocortisone (THE), Tetrahydrocortisol 
(THF) and 5a-Tetrahydrocortisol (5a-THF) were higher in patients before 
haemodialysis when compared to healthy controls. Plasma cortisone concentrations 
were also lower in this group, whereas there was no significant difference in cortisol 
concentrations for the two groups. The ratios of cortisol to cortisone and the ratio of 
their respective metabolites were significantly higher in the patients treated by 
dialysis, reflecting reduced 11β-HSD-2 activity (i.e. reduced elimination of GC) 
(Figure 1.5). They postulated either the presence of an inhibitory factor present in 
uraemic conditions or a reduced number of cells expressing 11β-HSD-2 due to lower 
nephron mass (90). 
 
 
 
Figure 1.5 Formation of the metabolites of cortisol (F) and cortisone (E).  
Reduction of 11β-HSD-2 activity leads to an increase in cortisol/cortisone ratio and 
(5a-THF + THF)/THE. Adapted from N’Gankam et al. (90). 
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1.4.5.4 11b-HSDs in Skin 
A limited number of studies have previously demonstrated the presence of 11β-HSD-
1 in skin (73, 91). Paul Stewart’s group have led further investigations of 11β-HSD-
1 in skin and wound healing, describing the localisation of the enzyme to epidermal 
keratinocytes and dermal fibroblasts in both human and mouse skin as well as outer 
hair follicle root sheath cells in mice (92-94). In addition Lee et al. have observed 
immunoreactivity within sebaceous glands of normal skin and in inflammatory acne 
lesions (95). 
 
Tiganescu et al. presented a trend towards increased reductase activity with increased 
donor age using 11β-HSD-1 activity assays performed on human skin tissue explants. 
They found 11β-HSD-2 activity was also present; however, this did not correlate with 
age. Supporting these findings, they demonstrated increased 11β-HSD-1 mRNA with 
donor age in primary cultures of human dermal fibroblast cells from sites exposed 
and protected from sunlight (lower outer versus inner upper arm).  GRa, H6PDH and 
11β-HSD-2 mRNA did not correlate with age or site. GC stimulation resulted in an 
upregulation of 11β-HSD-1 mRNA, although GRa and 11β-HSD-2 mRNA was down 
regulated. No regulatory effect was observed in H6PDH mRNA expression in 
response to stimulation with the same dose of cortisol (92). Using a global 11β-HSD-
1 KO mouse model, they observed that aged KO mice had skin histological findings 
similar to young wild type controls with more organized collagen deposition and less 
dermal atrophy (93). These findings suggest elevated 11β-HSD-1 activity in aged skin 
leads to increased active cortisol production with its concomitant adverse features. In 
addition, the group examined the regulation of the 11β-HSDs in a mouse wound 
healing model. They noted a peak increase in 11β-HSD-1 gene expression and 11β-
HSD-1 protein at day 2 post wounding, declining at day 4 to non-significant levels at 
day 8. 11β-HSD-2, NADPH, H6PDH and GRa  mRNA was unaffected by wound 
healing. 11β-HSD-1 activity was enhanced at day 2 and 4, whereas 11β-HSD-2 
activity was negligible and unchanged post wounding (94). Topical 11β-HSD-1 
inhibitor treatment was observed to accelerate healing of full thickness dorsal skin 
wounds in mice, alluding to an adverse role of the enzyme in healing (93). 
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1.4.5.5 Regulatory Factors of 11b-HSD-1 in Skin 
1.4.5.5.1 Ultraviolet Radiation (UVR) 
Different UV bandwidths have been shown to have a differing effect on the 
expression of 11β-HSD-1 and 11β-HSD-2 in skin. UVB and UVC increase 11β-HSD-
1 protein expression and decrease GRa expression whereas UVA has no such effect. 
In contrast, UVA increases 11β-HSD-2 protein expression (96). Tiganescu et al. 2015 
examined the effect of UVB radiation on 11β-HSD-1 expression in mice in vivo in 
more detail. They found mRNA expression for 11β-HSD-1 and H6PDH was 
significantly increased at day 1 post exposure to a single dose of UVB compared to 
control non-exposed mice. The mRNA levels remained raised at day 3 and 7; 
however, this was not statistically different.  GRa mRNA expression in contrast was 
30% lower in the control group at day 3, suggesting a negative feedback mechanism. 
11β-HSD-1 protein expression was detected at day 3 post exposure, with a significant 
difference observed when compared to the control group. Histological examination 
of skin at day 3 post exposure noted a hyper proliferative epidermis, with 11β-HSD-
1, detected by immunofluorescence, seen in the epidermis (concentrated in stratum 
basale layer, more diffuse in suprabasal layers and absent in stratum corneum), hair 
follicle outer root sheath (basal epidermal keratinocytes), with less 11β-HSD-1 
detected in dermal fibroblasts. They also noted a positive correlation with 11β-HSD-
1 activity and trans-epidermal water loss, suggesting disruption of skin barrier 
integrity (97). Hence, epidermal keratinocytes have a significant role in the regulation 
of 11β-HSD-1 expression and activity in response to UVR. 
 
1.4.5.5.2 Inflammatory Cytokines 
Pro-inflammatory mediators such as TNF-a and IL-1 have been shown to be inducers 
of 11β-HSD-1 in various cell types (preadipocytes, mesangial cells, luteinised 
granulomas cells, ovarian surface epithelial cells, synovial fibroblasts, bone marrow 
fibroblasts) promoting GC availability at the local level (91). Ito et al. demonstrated 
that IL-1b and TNF-a increased protein expression of 11β-HSD-1 in normal human 
keratinocyte cells as well as increasing cortisol concentrations in the culture media 
(63). Cells stimulated by these cytokines produced IL-6 and IL-8, an effect which was 
abrogated by 11β-HSD-1 Small Interfering RNA (siRNA) knock down. These 
findings suggested that pro-inflammatory mediators stimulate 11β-HSD-1 expression 
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which in turn can also stimulate production of further inflammatory cytokines. 
Additionally, exposure to low or high doses of cortisol had opposing effects on the 
production of IL-6 in keratinocytes, indicating that the influence of 11β-HSD-1 
activity within cells could be crucial to the concentration of GC present and 
consequently whether inflammatory mediators are produced or suppressed. Vukelic 
et al. confirmed this increase in cortisol synthesis in human keratinocytes treated with 
IL-1b and conversely an inhibition of cortisol synthesis in cells treated with insulin-
like growth factor-1. They showed correlating changes in CYP11B1 mRNA 
expression but did not demonstrate its protein expression or enzyme activity in cell 
culture. Unfortunately, they did not concurrently investigate 11β-HSD-1 protein 
expression or activity to definitively delineate whether the increased cortisol 
concentrations were from de novo steroidogenesis or via the 11β-HSDs or from both 
pathways (98). 
 
1.4.5.5.3 Pharmacological Inhibition 
Inhibitors of the 11b-HSDs have been identified and studied extensively (99-104). In 
humans, the non-selective compound carbenoxolone was amongst the first to be 
utilised (40). Both 11b-HSD-1 and 11b-HSD-2 are inhibited by carbenoxolone 
thereby limiting its clinical potential due to the resultant hypokalaemia and 
hypertension. Selective 11b-HSD-1 inhibitors are sought to overcome these issues.  
Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is a naturally occurring compound 
from the roots of Rheum officinale Baill, a Chinese herb (105). Emodin has been 
shown to have numerous pharmacological effects including antibacterial, antiviral, 
immunosuppressive, anti-tumour, anti-diabetic and anti-inflammatory effects (106). 
Tang et al. observed enhanced cutaneous wound healing in rats where a topical 
application of emodin was utilized, demonstrating increased wound contraction, 
angiogenesis and wound collagen content (107). They found that emodin increased 
Transforming Growth Factor Beta 1 (TGF-b1) mRNA in wound tissue and identified 
upregulation of the intracellular proteins Smad 2 and 3 that could result in 
transcriptional changes of TGF-b inducible genes known to modulate the wound 
healing process. They also found a down-regulation of Smad 7 which acts as an 
inhibitor to the TGF-b1 receptor (107). Radha et al. observed increased fibrinolytic 
activity of fibroblast cells with the use of emodin, demonstrating an upregulation of 
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the urokinase plasminogen activator gene, protein and activity. They noted attenuated 
activity with ascorbic acid co-treatment, postulating the generation of reactive oxygen 
species as a mechanism for this upregulation. Emodin also caused an increase in 
cellular migration in an in vitro wound healing model (108). Feng et al. demonstrated 
that emodin is a potent and selective 11b-HSD-1 inhibitor in humans and mice, with 
no effect on 11b-HSD-2 (109). The contribution of 11b-HSD-1 inhibition by emodin 
in wound healing has yet to be ascertained. 
 
1.5 Wound Healing 
Wound healing after injury is a complex biological process involving diverse skin 
compartments as well as multitude of cellular constituents, growth factors, cytokines 
and is influenced by systemic factors such as the presence of diabetes mellitus, 
vascular disease and impaired nutritional or immunological status (110). Restoration 
of the functional barrier is the aim; however, failure in the process at any stage can 
result in chronic wound formation with its associated health and economic burden 
(111). 
 
1.5.1 Phases of Healing 
The normal process of healing occurs as a continuum, however to assist in further 
comprehending the underlying processes, it has been defined crudely into three 
phases; an inflammatory period followed by a proliferative and finally a remodelling 
period (110, 112, 113). After injury, the clotting cascade is initiated; thrombin 
activates fibrin formation and promotes its deposition into a mesh-like structure that 
can form the foundations to recruit cells including inflammatory cells such as 
neutrophils, macrophages and T-lymphocytes (114). Platelets are also recruited to the 
site of damage whereby they aggregate and degranulate releasing cytokines and 
chemokines that promote this process and stabilise the clot formation, achieving 
haemostasis (115). In parallel, the inflammatory response is propagated at the wound 
site with the clearance of dead or injured cells by phagocytosis (116). Additionally, 
bacteria are engulfed to protect against infection. In the presence of a high bacterial 
load, inflammatory cell influx is sustained resulting in an imbalance between 
inflammatory and anti-inflammatory signals, leading to delayed healing (117). 
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In the proliferative phase, fibroblasts and keratinocytes are recruited to the wound to 
begin the repair process (116, 118, 119). A sufficient blood supply is essential for all 
cells at the wound site as they require nutrients and oxygen to thrive. Angiogenesis is 
crucial for this to occur. Existing blood vessels vasodilate under the influence of 
histamine, prostaglandins and kinins and become more permeable, allowing leucocyte 
extravasation (from the intravascular to extravascular space) to promote phagocytic 
debridement and decontamination of the wound site (112). Macrophages can secrete 
endothelial chemotactic factors and growth factors as well as proteases which 
encourage endothelial cells to detach from the embedded endothelium (112). 
Endothelial cells can then divide and migrate towards the released angiogenic factors, 
laying down new vessels in an organised fashion (120). Sprouting of new vessels is 
stimulated by hypoxia and acidosis within the microenvironment (112). In turn, 
Hypoxia Inducible Factor (HIF) is released which can activate genes for other 
angiogenic factors such as VEGF (121). The endothelial cells of the new vessels 
mature and form new basal laminae, surrounded by a pericyte layer (122). The main 
aim of the proliferative phase is the formation of granulation tissue which consists of 
inflammatory cells, fibroblasts, neovasculature with a matrix of fibronectin, collagen, 
proteoglycans and glycosaminoglycans (112). Fibroblasts are an important cell type 
in promoting granulation tissue formation. Their migration and proliferation is 
stimulated by fibronectin as well as released growth factors such as fibroblast growth 
factor, platelet derived and TGF-β (112, 113, 123). Fibroblasts use fibrin and 
fibronectin deposited like a scaffold to migrate across the wound area, secreting 
procollagen, glycosaminoglycans, hyaluronan, chondroitin sulphate into the 
extracellular space thereby providing a more stable network for further fibroblast 
migration (113). 
 
Keratinocytes play a key role in epithelialization. They migrate first across the wound 
site, then proliferate from uninjured keratinocytes at the wound edge, meeting in the 
middle of the wound where the process is halted by contact inhibition (112). To 
achieve this, desmosomal and hemi-desmosomal interactions that anchor cells to each 
other and the Extracellular Matrix (ECM) are disrupted (124). Intracellular actin 
microfilaments form to allow keratinocytes to creep over the wound surface by 
interacting with the matrix of fibrin crosslinked with fibronectin and collagen (124, 
125). Keratinocytes must be able to dissolve the clot that has formed at the 
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haemostatic stage as well as interposing debris or ECM within its migration path. To 
assist with this, plasminogen activator is released as well as collagenases and 
proteases (112). Once migration has ceased, proteins can be secreted to form a new 
BM. The desmosomal and hemi-desmosomal interactions are re-formed to anchor 
cells to the BM. 
 
Finally, wound contraction is observed where fibroblasts differentiate into 
myofibroblasts and contract the wound edges in a centripetal fashion. Further 
collagen is laid down at the same time to reinforce the wound (123). 
 
In the final phase of wound healing, remodelling of the ECM occurs. The main feature 
of this is collagen remodelling under the regulation of collagenases and matrix 
metalloproteinases (126). Collagen type III is replaced by a greater proportion of 
collagen type I, which becomes more organized in structure (increased diameter of 
fibrils, increased inter-fibril binding, and rearrangement of fibrils). In addition, 
fibronectin gradually disappears, and water and proteoglycan content decreases (112, 
113). 
 
1.5.2 Wound Healing in Uraemic Skin 
In the 1960s Nayman noted breakdown of abdominal wounds in the uraemic state and 
set out to investigate the effect of induction of acute renal failure with uranium nitrate 
in wound healing post-laparotomy in dogs, as well as the ability of haemodialysis to 
prevent wound breakdown. He reported that induction of acute renal failure within 
the first 6-7 days post laparotomy resulted in wound breakdown, but occurrence of 
renal impairment beyond this point had no effect upon the wound. Early and frequent 
haemodialysis abrogated this effect on wounds (127). Histological studies in mice 
revealed significant impairment of healing in uranium nitrate treated groups with a 
reduction in granulation tissue formation and inhibition of proliferation of fibroblasts 
and endothelial cells (128). 
 
In the last 30-40 years, there has been a paucity of published in vivo studies of wound 
healing in CKD with no firmly established model available to examine the 
interactions of uraemia with healing. Seth et al. developed a surgical excisional 
wound healing murine model of CKD in 2013. They demonstrated that animals with 
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CKD had significantly disrupted epithelization kinetics and granulation tissue 
deposition rates compared to control animals. The wounds of CKD mice showed 
significantly less proliferating cells and a significant reduction in angiogenesis 
compared to their controls. Of note, uraemic mice displayed an increased 
inflammatory state during early stages post-wounding which was maintained to day 
14 (38). 
 
1.6 Hypothesis and Aims 
We predict that the cortisol producing enzyme 11b-HSD-1, which is highly expressed 
in the skin, is activated in the uraemic state with resultant poor wound healing in our 
CKD patient population. 
 
Aims: 
• To determine the presence or absence of 11b-HSD-1 and 11b-HSD-2 in skin 
in uraemia 
• To determine the activity of 11b-HSD-1 in skin in uraemia 
• To clarify the role 11b-HSD-1 plays in wound healing in uraemia 
• To investigate whether topical or systemic inhibition of skin 11b-HSD-1 can 
be harnessed to accelerate wound healing in uraemia 
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CHAPTER 2 
Materials and Methods 
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2.1 Cell Culture Techniques 
2.1.1 Cell Culture Models 
Cell culture is a technique used to study the normal physiology and biochemistry of 
cells, outside the complexity of the whole organism. The effects of drugs and toxins 
can be readily analysed by manipulation of the growth environment. To simulate the 
uraemic milieu compounds can be added to cell culture media, which in turn is used 
to culture cells of interest. IS and PC are two such solutes that have been shown to be 
retained in the serum of patients with CKD (129). Both substances originate from 
bacterial fermentation of protein in the colon. Tryptophan is degraded to indole, 
which is then hydroxylated and sulphonated to IS in the liver (130), whereas tyrosine 
(and to a lesser degree phenylalanine) is fermented to PC (131). 
 
IS was first isolated in 1911 by Obermayer and Popper where they found it to be 
present in high concentrations in the serum of patients with CKD (132).  Since then 
numerous researchers have studied its role in kidney disease, toxicity and methods to 
reduce plasma concentrations (133). IS is a small solute with a molecular weight of 
213 g/mol. It is 90% bound to proteins found in the plasma such as albumin (134). In 
normal functioning kidneys, it is cleared by tubular secretion. IS exists in an 
equilibrium between the bound and free state. As blood containing IS passes through 
the peritubular capillaries of the proximal tubules, unbound IS is taken up by proximal 
tubular cells via the Organic Anion Transporters OAT1 and OAT3 found on the 
basolateral surface. It then passes through apical membrane transporters into the 
tubular lumen. To maintain equilibrium, another molecule of IS will dissociate from 
the plasma proteins (135, 136). As haemodialysis cannot mimic this described tubular 
secretion, clearance of IS via haemodialysis is low at 25-30 mL/min compared to 
clearance of a water-soluble solute such as urea at 220 mL/min (134). 
 
PC is also a small solute with a molecular weight of 108.1 g/mol. It is almost 100% 
bound to plasma proteins (137). Like IS, it is poorly cleared on haemodialysis due to 
its protein bound nature (138). PC has been shown to alter cell permeability in bacteria 
(139),  block cell K+ channels (140) as well as inhibit the release of platelet activating 
factor by peritoneal macrophages in rats (141) and decrease endothelial wound repair 
(129). It’s concentration in the uraemic state was noted to decrease with the binding 
resin AST-120 (142). 
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2.1.2 Cell Culture Media and Buffers 
For cell culture, two primary cell populations from commercial sources were utilised. 
HDFs (Fisher Scientific Limited, Loughborough, UK) were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) containing 1000 mg/L glucose, L-glutamine, 
sodium bicarbonate and pyridoxine supplemented with 10% Foetal Bovine Serum 
(FBS) and 1% penicillin/streptomycin (10000 U penicillin and 10 mg streptomycin 
per mL) (all from Sigma-Aldrich, Poole, UK). HEKs (Fisher Scientific Ltd) were 
cultured in Gibco EpilifeTM medium containing 60 µM calcium supplemented with 
Human Keratinocyte Growth Supplement (HKGS, Fisher Scientific Ltd). 
 
Cells were cultured in T75 flasks containing 25 mL of appropriate medium in a 
humidified incubator at 37oC in a 95% air, 5% CO2 atmosphere. On attaining 70% 
confluence they were passaged as required. To mitigate against trypsin related cell 
damage, Trypsin Neutralizing Solution (Fisher Scientific Ltd) was added in 
equivalent quantities after the cells had detached from the flask by using 5 mL of an 
alternative enzyme; TrypLE™ Express Enzyme 1X (Fisher Scientific Ltd). The 10 
mL suspension was centrifuged at 650 g for 5 min. The cell pellet was re-suspended 
in 1 mL of the appropriate growth media, which was then added to the desired volume 
of filtered media for subsequent culture. 
 
To perform experiments, the cell pellets were suspended into a total volume of media 
such that 5 mL could be seeded into T25 flasks. Cells were incubated in complete 
media until they had achieved 70% confluence. Thereafter the media was removed 
and replaced with 5 mL media without supplements or antibiotics for 24 h prior to 
experimentation. Serum starvation was employed to bring all cells in to the same 
phase of the cell cycle and to control for the multitude of effects that the serum 
components may have on the outcomes being measured (143, 144). 
 
2.1.3 Simulation of Uraemia using Uraemic Toxins 
To simulate the uraemic milieu, two different solutes previously shown to accumulate 
in patients with CKD were investigated.  These are IS and PC. Cultured cells were 
treated at a range of concentrations of uraemic toxins, including dilutions greater and 
less than those found in patients with CKD (IS 10 µg/mL and PC 25 µg/mL). 
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IS (Sigma-Aldrich, Poole, Dorset, UK) was dissolved in double pass reverse osmosis 
purified water (RO) to make a stock solution of 10 mg/mL. Calculated volumes of IS 
stock were added to supplement-free cell culture media to achieve final 
concentrations of 25, 50 and 100 µg/mL. RO grade water was utilised as vehicle. 
Media from T25 flasks was aspirated, discarded and replaced with 3 mL IS 
experimental solution and incubated over a range of 1 - 48 h before the cells were 
lysed. 
 
PC was solubilised in Dimethyl Sulphoxide (DMSO) (both from Sigma-Aldrich) to 
make a stock solution of 10 mg/mL. Calculated volumes of PC stock were added to 
supplement-free cell culture media to achieve final concentrations of 10, 25 and 50 
µg/mL. DMSO was utilised as vehicle. Media from T25 flasks was aspirated, 
discarded and replaced with 3 mL PC experimental solution and incubated over a 
range of 1 - 48 h before the cells were lysed. 
 
2.1.4 Inhibition of 11b-HSD-1 by Emodin 
Emodin (Sigma-Aldrich) was solubilised in DMSO to make a stock solution of 10 
mM. Calculated volumes of emodin stock were added to supplement-free cell culture 
media to achieve final concentrations of 20, 50 and 100 µM. DMSO was utilised as 
the vehicle control. Media from T25 flasks was aspirated, discarded and replaced with 
3 mL emodin experimental solution and incubated over a range of 1 - 48 h. 
 
2.1.5 LDH Assay 
Prior to cell lysis, 1 mL of the cell culture media was removed from each T25 flask 
and transferred to a 1.5 mL Eppendorf tube (Fisher Scientific Ltd). The media was 
briefly centrifuged at 600 g for 3 min to remove any cell debris before performing a 
LDH cytotoxicity assay (Roche Diagnostics Limited, distributed by Sigma-Aldrich). 
100 µL supernatant was added to a clear bottomed 96-well plate before adding 100 
µL of reaction mixture (catalyst (diaphorase/NAD+ mixture) and dye solution 
(iodotetraxolium chloride and sodium lactate) in a ratio of 45:1). The plate was then 
protected from light for 5 min. A Dynex Technologies MRX TC II Microplate 
Absorbance Reader was used to measure absorbance at 490 nm after this period. 
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This colorimetric assay quantitates cytotoxicity based on the measurement of LDH 
activity released from the cytoplasm of damaged cells. Released LDH reduces NAD+ 
to NADH+ and H+ by oxidation of lactate to pyruvate. In the coupled enzymatic 
reaction, 2 H+ are transferred from the NADH+ H+ to the yellow tetrazolium salt (2-
[4-iodophenyl]-3-[4-nitrophenyl]-5-phenyltetrazolium chloride by the catalyst 
formulating a formazan product with an orange colour which can then be measured. 
 
2.1.6 Cell Lysis and Protein Extraction 
After media removal, the cells were washed in 3 mL ice-cold calcium and magnesium 
free phosphate buffered saline solution (Severn Biotech Limited, Kidderminster, UK) 
which was then aspirated and discarded. Prior to harvesting the cells with a plastic 
cell lifter (Fisher Scientific Ltd), 300 µL of Mammalian Protein Extraction Buffer 
(MEB) (GE Healthcare, distributed by VWR International Limited) supplemented 
with 1% of Calbiochem protease and phosphatase inhibitors (Merck, Watford, UK) 
was added to each T25 flask. The lysed products were collected into an Eppendorf 
tube for centrifugation at 16,000 g at 4oC for 15 min. The supernatant was collected 
for use in future work and stored at -80oC. 
 
2.1.7 Cell Viability Assay 
Cells were suspended in appropriate media before 100 µL was dispensed into 72 wells 
of a 96-well plate. The remaining 24 wells were left empty to use as negative controls. 
After 24 h, this media was aspirated and discarded before every well was replaced 
with 100 µL of either IS (0, 25, 50, 100 µg/mL), PC (0, 10, 25, 50 µg/mL) or emodin 
(0, 20, 50, 100 µM) experimental solutions in either complete or supplement-free 
media. To determine cell viability, the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega, Southampton, UK) was performed. 20 µL of the kit 
reagent was added to each well prior to incubation at 37oC in a 95% air, 5% CO2 
atmosphere for 1 hour. A Dynex Technologies MRX TC II Microplate Absorbance 
Reader was then used to measure absorbance at 490 nm. 
 
This assay employs the principle that viable cells can generate products such as 
NADPH that can reduce the tetrazolium compound, MTS (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium) in the 
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presence of an electron coupling reagent such as phenazine ethosulphate, into a 
soluble formazan product with a detectable colour. Upon cell death, the ability to 
reduce MTS is lost and less formazan product is formed. Hence, the number of viable 
cells is taken to be directly proportional to the production of the coloured formazan 
product which can be quantified by absorbance measurements. 
 
2.1.8 Scratch Assays with the JuLITM Stage Cell Imager  
Cells were suspended in appropriate media before 1mL was dispersed into each well 
of a 12-well plate. The plate was cultured in a humidified incubator at 37oC in a 95% 
air, 5% CO2 atmosphere. Upon attaining 70% confluence, 3 parallel vertical scratches 
were made in the middle of each well with a 20 µL graduated pipette tip. The media 
was aspirated and discarded before being replaced with 1mL of designated 
experimental solutions that had been pre-warmed to 37 oC either IS (0, 25, 50 or 100 
µg/mL), PC (0, 10, 25, 50 µg/mL) or emodin (0, 20, 50, 100 µM). The plate was 
placed on the JuLITM Stage cell imager and the most uniform scratch in each well was 
selected for serial imaging over 24 hours at 1 hour intervals. The inbuilt software uses 
image capture and time lapse recording to generate growth curves for each well by 
calculating the percentage healing across the scratch in each well at each time interval. 
The experiments were repeated using media without supplements or antibiotics for 
24 hours prior to scratching and to make up the IS, PC and emodin experimental 
solutions. 
 
2.2 In vivo and ex vivo Methods 
All in vivo work was carried out under Home Office Project License number PPL 
70/8350 with ethical approval from Queen Mary University of London. The 
principles of the 3Rs (replacement, reduction and refinement) were employed in the 
execution of all experiments. 
 
2.2.1 Adenine Diet Model 
Yokozawa et al. first showed in 1986 that feeding adenine to rats produced metabolic 
abnormalities like those found in patients with CKD (145). The formation of 2, 8-
Dihydroxyadenine (DHOA) by xanthine oxidase occurs secondary to the saturation 
of the enzyme adenine phosphoribosyltransferase by excess adenine.  Instead of the 
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formation of adenosine monophosphate and subsequently allantoin 25, DHOA is 
formed which is poorly water soluble and hence precipitates out of urine. DHOA has 
been shown to cause a crystal nephropathy as well as renal stones, with the potential 
to cause obstruction and subsequent hydronephrosis (146). Histologically, needle 
shaped crystals are deposited within the lumen of the renal tubule causing 
pathological expansion of the tubule. Although there is a predisposition for the 
proximal tubule, crystals can be found along the entire length of the tubule both in the 
renal cortex and the medulla. Interstitial oedema and fibrosis can result. Granulomas 
composed of histiocytes and multinucleate giant cells are observed around these 
crystals causing a granulomatous interstitial nephritis and subsequent renal function 
impairment. The glomerulus itself is spared in this process (147). 
 
By altering the concentration of adenine within the diet as well as the duration it is 
given to animals, renal failure of varying severity can be studied. Okada et al. showed 
that rats fed 0.75% adenine for 2 weeks developed reversible, partially recoverable 
renal failure as compared to those fed for 4 weeks that developed non-progressive, 
irreversible damage and those at 6 weeks that had progressive, irreversible renal 
failure. At 6 weeks, a rise in serum sodium, potassium, hypoproteinaemia, leukopenia 
and a higher mortality rate were noted prompting the authors to conclude that to 
generate a favourable experimental model, 4-5 weeks of 0.75% adenine feed in rats 
was sufficient (147). 
 
2.2.2 Subtotal Nephrectomy (SNx) Model 
An alternative model used by our research group is that of SNx whereby 5/6th of renal 
mass is removed in a 2-stage procedure. Initially, a left flank incision is made under 
general anaesthesia. Underlying musculature is blunt dissected to the parietal 
peritoneum. A further incision is made through which the kidney is carefully 
externalised. After removal of the perinephric fat and renal capsule, an arterial clamp 
is placed across the hilum. Approximately 2/3rds of the renal parenchyma is removed 
from the upper and lower renal poles as well as the lateral surface. The arterial clamp 
is then removed and haemostasis achieved by applying manual pressure to the cut 
surfaces. The kidney is returned to the abdomen. 1 mL of sterile saline is instilled into 
the abdominal cavity to compensate for surgical fluid losses.  The musculature is 
sutured and the skin incision stapled closed. Subcutaneous analgesia is then 
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administered.  2 weeks after recovery from the first operative stage, the animals are 
anaesthetized and a contralateral right flank incision made. The kidney is externalised. 
After applying the arterial clamp, the renal artery and vein are ligated. The whole 
kidney is excised distal to the ties. Sterile saline is instilled, and the incisions closed 
as before. After recovery, animals are given 4 weeks to recover during which they 
develop a uraemic state. Sham operated animals undergo the same anaesthetic, 
incisions, externalisation of kidneys, decapsulation and arterial clamping. However, 
no renal tissue is excised. These animals form suitable controls for experimental work 
(148). The SNx model generates a more restrained increase in serum urea and 
creatinine which is sustained from 3 weeks post-surgery (149). 
 
2.2.3 Rat Uraemic Model 
6-week old male Wistar Rats (Charles River Laboratories, Kent, UK) were housed in 
a temperature controlled facility. 12 h light and dark cycles were maintained as was 
free access to water and standard chow (Rat and Mouse No. 1 Maintenance, SDS 
Diets, Essex, UK). Following a 1-week acclimatization period, the animals were 
randomly assigned to 2 groups: standard chow supplemented with 0.75% adenine 
(SDS Diets) to develop a uraemic phenotype or standard chow alone (control 
animals). Over the subsequent 3 weeks, survival, growth rate and general well-being 
were closely monitored. 
 
2.2.3.1 Rat Wound Healing Model 
Animals were weighed and examined for general health before undergoing wounding. 
Under 5 L/min IsoFlo 100% v/v (isoflurane, Zoetis, London, UK) inhaled anaesthesia, 
the dorsum was shaved with electric clippers. Chlorhexidine (Fisher Scientific Ltd) 
was used to clean the skin. Under 1.5 L/min isoflurane anaesthesia, 30 µL Vetergesic 
(buprenorphine, Ceva Animal Health Limited, Amersham, UK) was injected 
subcutaneously. The dorsal skin was drawn together in a fold. One 5 mm Stiefel punch 
biopsy tool (Schuco, Watford, UK) was employed to make 2 wounds through the skin 
with one punch; entrance wound A and exit wound B (Figure 2.1). The punched-out 
skin was bisected; half was snap frozen in liquid nitrogen (later stored at -80oC) and 
the remaining half mounted onto Polyvinylidene Difluoride (PVDF) 0.45 µm 
membrane (Fisher Scientific Ltd), stored in 10% neutral buffered formalin solution 
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(Sigma-Aldrich) and then transferred to 70% ethanol (VWR International Ltd) 24 h 
later. Animals were observed to recover from anaesthesia before returning to cages. 
 
2.2.3.2 Topical Emodin in Rat Wound Healing Model 
Emodin (Fluorochem Limited, Glossop, UK) was solubilised into 2% Carbopol®934 
(Enzo Lifesciences (UK) Limited, Exeter, UK) using triethylamine (Sigma-Aldrich) 
to form a gel with a final concentration of 500 µg/mL or 1000 µg/mL. 0.5 mL of drug 
or 2% Carbopol®934 as vehicle was massaged into each wound once daily from day 
0 - 4 after wound healing. Animals were culled at day 7. 
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Figure 2.1 Images of rat wound healing procedure. A) skin preparation, B & C) 
anaesthesia administration and D) wounding with punch tool. 
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2.2.3.3 Systemic Emodin in Rat Wound Healing Model 
Emodin (Fluorochem Limited) 100 mg/kg or vehicle 10% ethanol (VWR 
International Ltd) was administered once daily to animals by oral gavage from day 0-
2. Animals were then culled at day 3. For a secondary experiment, emodin 100mg/kg 
or vehicle 10% ethanol was administered once daily from day 0-4 after wound healing 
with animals being culled at day 7.  
 
2.2.4 Tissue Retrieval 
All animals were culled in accordance with Home Office (Animals Scientific 
Procedures Act 1986) Schedule 1 regulations. After weighing animals, a terminal 
dose of thiopentone (Archimedes Pharma, Reading, UK) was administered 
intraperitoneally. Blood was obtained by cardiac puncture in a heparin sodium 
(Wockhardt Limited, Wrexham, UK) coated 2 mL syringe. 1 sample was left to clot 
at room temperature for 2 h before centrifugation for 20 min at 2000 g.  Serum was 
transferred to a clean Eppendorf and stored at -20oC for corticosterone measurement. 
A second sample was stored at 4oC, centrifuged at 7000 g for 3 min. The serum 
obtained was sent to IDEXX BioResearch Laboratories, Ludwigsburg, Germany for 
biochemical analysis. 
 
The dimensions of wounds A and B were measured. The wounds and a small 
surrounding area of skin were excised and bisected; half was snap frozen in liquid 
nitrogen and the remaining half mounted onto PVDF membrane (Fisher Scientific 
Ltd), stored in 10% neutral buffered formalin solution (Sigma-Aldrich) and then 
transferred to 70% ethanol (VWR International Ltd) 24 h later. Organs of interest 
including liver and non-wounded skin were concurrently snap frozen in liquid 
nitrogen and then stored at -80oC. 
 
2.2.5 Tissue Homogenisation for Protein Isolation 
Tissues retrieved from -80oC were stored on the bench in liquid nitrogen until ready 
for use.  Skin samples were dissected with scalpel and forceps to remove 
subcutaneous adipose and muscular tissue. After cutting into small pieces, the sample 
was re-frozen in liquid nitrogen. A ceramic pestle and mortar with rough surfaces was 
cooled with liquid nitrogen before adding the sample and manually grinding until a 
powder formed. Liquid nitrogen was replenished as required until this had been 
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achieved. 1 mL of MEB (GE Healthcare) with 1% Calbiochem protease and 
phosphatase inhibitors was added to the powder before transferring to an Eppendorf 
and returning to liquid nitrogen. All samples were thawed together at room 
temperature before centrifugation at 16000 g for 15 min at 4oC. The supernatant was 
preserved, aliquoted and stored at -80oC until ready for use for protein quantification 
or western blotting. 
 
2.2.6 Tissue Homogenisation for RNA Isolation 
All equipment and laboratory surfaces were cleaned with RNase Away (Molecular 
BioProducts, Fisher Scientific Ltd). Care was taken to minimize the introduction of 
RNases by using autoclaved laboratory consumables and regularly changing gloves. 
Tissue retrieved from -80oC was stored in liquid nitrogen until ready for use.  Skin 
samples were dissected with scalpel and forceps to remove subcutaneous adipose and 
muscular tissue. After cutting into small pieces, the sample was re-frozen in liquid 
nitrogen. A ceramic pestle and mortar with rough surfaces was cooled with liquid 
nitrogen, before adding the sample and manually grinding until a powder formed. 
Liquid nitrogen was continuously replenished until this had been achieved. 300 µL 
Buffer RLT (Qiagen RNeasy® Fibrous Tissue Mini Kit, Manchester, UK) with 10 
µL/mL b-mercaptoethanol (Sigma-Aldrich) was added to approximately 30 mg of 
tissue. Lysates were stored at -80oC until ready for use. 
 
2.3 Western Blotting 
2.3.1 Protein Quantification 
Protein concentration was determined using a bicinchoninic acid (BCA) assay 
(Pierce™ BCA Protein Assay Kit, Fisher Scientific Ltd).  Bovine serum albumin 
(Sigma-Aldrich) diluted with RO grade water was used to create calibrants of known 
concentrations (0 – 2000 µg/mL) against which cell lysate or tissue homogenate 
protein concentration could be measured. 25 µL of standards or samples was added 
to a clear bottomed 96-well plate. 200 µL of working reagent (50:1 reagent A to 
reagent B) was then added to each well before mixing and then incubating the plate 
for 30 min at 37oC. A Dynex Technologies MRX TC II Microplate Absorbance 
Reader was used to measure absorbance at 550 nm after this time. 
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This assay allows for the colorimetric detection and quantitation of protein in samples. 
Cu2+ is reduced to Cu1+ by protein in an alkaline medium (the biuret reaction). Two 
molecules of BCA then chelate with one cuprous cation, forming a purple coloured 
product which can be measured spectrophoretically. 
 
2.3.2 Sample Preparation 
30 µL sample and 10 µL NuPageÒ Sample Loading Buffer 4X (Fisher Scientific Ltd) 
were heated in a water bath at 75oC for 15 min to denature and reduce disulphide 
bonds. A standardized concentration of protein was used for each western blot (in the 
range of 30 to 60 µg protein per well). 
 
2.3.3 Gel Electrophoresis 
The XCell SureLockTM Mini-Cell (Fisher Scientific Ltd) apparatus was assembled for 
electrophoresis. Pre-cast 4-12% Bis-Tris gels (NuPage™ Novex™ Fisher Scientific 
Ltd) with the appropriate number of wells (10, 12 or 15) were chosen according to 
the number of samples to be run. Gels were removed from packaging, discarding the 
preservative solution within. Combs inset to form loading wells were carefully 
removed and rinsed with MOPS solution (50 mL NuPage® MOPS SDS Running 
Buffer 20X, Fisher Scientific Ltd and 950 mL RO grade water). Gels were placed in 
the apparatus and clamped in situ. MOPS solution was used to fill the space between 
gels to ensure no leakage (upper buffer chamber). Samples were loaded alongside a 
marker (Cruz MarkerTM Molecular Weight Standards: sc-2035, Insight 
Biotechnology, Wembley, UK). The remaining MOPS solution was used to fill the 
Mini-Cell before running at 200 V for 1 h. 
 
2.3.4 Protein Transfer 
Transfer buffer was made to transfer 2 membranes simultaneously as follows: 200 
mL methanol (VWR International Ltd), 50 mL transfer buffer (NuPage® Transfer 
Buffer 20X, Thermo Fisher Scientific) and 750 mL RO grade water. This was used 
to soak blotting pads and 2.5 mm thick filter paper. PVDF 0.45 µm membrane 
(Thermo Fisher Scientific) was cut to size and pre-soaked in 100% methanol (VWR 
International Ltd) for 2 min. The pre-cast gels were opened, PVDF membrane placed 
on top, ensuring no air bubbles were present, and both incorporated into the transfer 
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‘sandwich’ made with blotting pads and filter paper. This was inserted into the Mini-
Cell and the clamp applied. Transfer buffer was used to fill the upper buffer chamber 
and RO water used to fill the lower buffer chamber. Protein transfer was performed 
over 2 h at 30 V. 
 
2.3.5 Blocking and Detection 
Non-specific protein binding was blocked by incubating the membranes in a 
commercial blocking buffer (Starting Block™(TBS) Blocking Buffer, Thermo Fisher 
Scientific) for 30 min.  The membranes were then incubated with either anti-rabbit 
11β-HSD-1 antibody or anti-rabbit 11β-HSD-2 (OABF01282 and OABB00330 both 
Aviva Systems Biology, Insight Biotechnology) diluted to an optimized concentration 
of 1:1000 in blocking buffer overnight, with shaking, at 4oC. The membranes were 
then washed three times in Tris Buffered Saline (TBS 10X) (Severn Biotech Limited) 
plus 0.05% Tween-20 (Fisher Scientific Ltd) for 10 min before incubating with goat 
derived anti-rabbit Immunoglobulin G (IgG) conjugated to Horseradish Peroxidase 
(HRP) (sc-2030, Santa Cruz Biotechnology, obtained from Insight Biotechnology) 
diluted to 1:4000 for 1 h at room temperature. After three further 10 min washes in 
TBS-T, protein bands were detected using the PierceTM ECL Western Blotting 
Substrate Kit (Fisher Scientific Ltd) and Amersham Hyperfilm ECL (GE Healthcare). 
 
To confirm accurate protein loading, membranes were agitated in Restore™ PLUS 
Western Blot Stripping Buffer (Fisher Scientific Ltd) for 20 min, washed in TBS-T 
and then incubated for 15 min at room temperature with anti-rabbit Glyceraldehyde 
3-Phosphate Dehydrogenase (GAPDH) (G9545, Sigma-Aldrich) at a concentration 
of 1:5000. Following three 5 min TBS-T washes, the membranes were incubated with 
anti-rabbit IgG-HRP (Santa Cruz Biotechnology) at a concentration of 1:10000 for 
15 min at room temperature, before being washed thrice in TBS-T. Protein bands 
were detected using the aforementioned ECL kit and film. 
 
2.3.6 Western Blot Analysis 
Image J software (imagej.nih.gov) was utilised to measure protein band intensity from 
western blot images. 11β-HSD-1 and 11β-HSD-2 expression was normalised to that 
of GAPDH. 
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2.4 ELISA 
Commercially provided competitive enzyme immunoassays for cortisol and 
corticosterone were utilized (Bio-Techne, Abingdon, UK). Using these assays, 
corticosterone concentrations can be measured within the range of 0.012 - 0.047 
ng/mL and cortisol within the range of 0.030 – 0.111 ng/mL. Cortisol or 
corticosterone in samples competes with a fixed amount of HRP-conjugated 
cortisol/corticosterone which is added alongside an antibody specific to the steroid to 
a microplate coated with a complementary IgG antibody. After washing steps to 
remove excess unbound sample, HRP-conjugate and antibody, a substrate solution is 
added to the wells to determine bound HRP activity. The reaction is terminated with 
a stop solution after 30 min. The absorbance is read at 490 nm on Dynex Technologies 
MRX TC II Microplate Absorbance Reader. The intensity of the colour generated is 
inversely proportional to the concentration of steroid in the sample. A standard curve 
is generated from a stock calibrator provided with the kit by which the concentration 
of cortisol or corticosterone in the test samples can be determined. These assays will 
measure de novo (as well as residual) steroidogenesis in the skin or cell culture sample 
from the collected media. 
 
2.4.1 Cortisol ELISA 
Cortisol measurements were determined from cell culture media aspirated from T25 
flasks used for IS, PC and emodin experiments. Media was stored at -20oC until ready 
for use. The manufacturer’s protocol was followed as directed. 
 
2.4.2 Serum Corticosterone ELISA 
Serum corticosterone concentrations were quantified in blood collected from animals 
at the time of culling. After centrifugation for 20 min at 2000 g, serum was stored at 
-20oC until ready for use. To remove possible contaminating proteins and protein 
bound corticosterone, 150 µL of sample was added to 150 µL of Pre-Treatment E 
(provided by the kit consisting of 0.6 N trichloracetic acid) in a microfuge tube, mixed 
and incubated at room temperature for 15 min. After centrifugation at 12000 g for 4 
min, the supernatant was used in the assay as per the manufacturer’s protocol. 
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2.4.3 Skin Corticosterone ELISA 
Skin samples from in vivo studies (2.2.3.1 Wound Healing, 2.2.3.2 Topical Emodin 
in Rodent Wound Healing and 2.2.3.3 Systemic Emodin in Rodent Wound Healing) 
were retrieved from storage at -80oC. After removing subcutaneous adipose and 
muscle, a small section was cut. These sections were weighed and placed at the air: 
liquid interface of a 24 well plate prepared with 1 mL serum-free DMEM added per 
well. The plate was incubated in a humidified incubator at 37oC in a 95% air, 5% CO2 
atmosphere for 24 h. The media was aspirated, centrifuged at 16000 g for 15 min and 
then assayed as per the manufacturer’s protocol. 
 
2.5 PCR 
2.5.1 RNA Extraction 
RNA was extracted from tissue homogenates using the RNeasy® Fibrous Tissue Mini 
Kit (Qiagen Ltd, Manchester, UK). Samples were lysed in a buffer containing 
guanidine thiocyanate (RLT) before dilution with RNase-free water. Proteinase K was 
added to assist with removal of contractile proteins, connective tissue and collagen 
and the samples were then heated to 55oC for 10 min to optimize this reaction. After 
centrifugation, the debris that had pelleted was discarded. The supernatants were 
mixed with ethanol and centrifuged through the RNeasy spin columns contained in 
the kit. (RNA binds to the silica membrane therein). To eliminate contaminating DNA 
that may have also been present, DNase I (Qiagen) was incorporated for on-column 
elimination. Addition of further buffers contained within the kit (RW1 and RPE) 
followed by centrifugation was employed to wash away contaminants, before RNA 
was eluted in RNase-free water. RNA was stored at -80oC until ready for use. 
 
2.5.2 Estimation of RNA Purity and Quantity 
RNA integrity and quantity was ascertained using a Nanodrop (Thermo Scientific 
Nanodrop 2000c Spectrophotometer). An A260/280 ratio of >2.0 was deemed 
sufficient to proceed. 
 
2.5.3 Reverse Transcription 
250 ng of the extracted RNA from each sample and from Rat XpressRef Universal 
Total RNA (Qiagen) were reverse transcribed using the Maxima First Strand cDNA 
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Synthesis Kit (Fisher Scientific). 20 µL 5X Reaction Mix plus 10 µL Maxima Enzyme 
Mix was added to the RNA in a microfuge tube and nuclease free water used to make 
up a total reaction volume of 100 µL. After gentle mixing, the following conditions 
were run in a G-StormTM GSI thermal cycler: 10 min at 25oC, 15 min at 50oC followed 
by reaction termination by heating to 85oC for 5 min. Products were stored at -80oC 
until ready for use. 
 
2.5.4 PCR of Complementary DNA (cDNA) 
Quantitative PCR of cDNA was performed on skin samples for 11β-HSD-1 and 11β-
HSD-2. Concurrently, the same skin samples were processed to assay the 
housekeeping gene Beta 2 Microglobulin (B2M). TaqMan® Gene Expression assays 
(Thermo Fisher Scientific) were utilised. Each assay contains a pair of unlabelled 
primers as well as a TaqMan® probe with a FAMTM dye label on the 5’ end and a 
Minor Groove Binder (MGB) and Non-Fluorescent Quencher (NFQ) on the 3’ end. 
The first step of cycling involves a temperature rise which denatures the double 
stranded cDNA. At this stage, the signal from the FAMTM dye at the 5’ end is 
quenched by the NFQ on the 3’ end. As the reaction temperature is then lowered, the 
primers and probe anneal to their target sequences. TaqDNA polymerase synthesizes 
new strands of DNA using the available primers and template. When the enzyme 
reaches a TaqMan® probe, its 5’ nuclease activity cleaves the probe separating the 
FAMTM dye from the NFQ. As each cycle of PCR proceeds, more dye molecules are 
released and unquenched. The increase in fluorescence is proportional to the amount 
of target synthesized and can be measured with a compatible cycler (Figure 2.2). 
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Figure 2.2 Overview of TaqMan® based PCR reactions. Adapted from 
www.thermofisher.com (150).  
 
 
DNA standards of 5 known concentrations were made for each gene of interest by a 
1 in 10 serial dilution of the cDNA transcribed from the Rat XpressRef Universal 
Total RNA (2, 0.2, 0.02, 0.002 and 0.0002 ng/µL). 1 µL 20X TaqMan® Gene 
Expression Assay (11β-HSD-1 Rn00567167_m1 or 11β-HSD-2 
Rn04341420_g1/Rn00492539_m1 or B2M Rn03928990_g1) plus 10 µL 2X Maxima 
probe/ROX qPCR Master Mix (Thermo Fisher Scientific) was added to 2 µL sample 
cDNA, DNA standard or RNase-free water for a no template control. RNase-free 
water was added to make the total reaction volume 20 µL.  Each sample was run in 
duplicate in a Rotor-Disc 100 ring. The ring was then sealed with Rotor-Disc Heat-
Sealing Film (Qiagen) and the Rotor-Disc Heat Sealer (Qiagen). A Corbett Rotor 
Gene 6000 Real Time PCR machine was used to run the samples under the following 
conditions: 1 cycle 10 min at 95oC, 40 cycles 15 s at 95oC and 50 cycles 60 s at 60oC. 
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Gene of Interest Sequence 
11b-HSD-1 TCTCCTCCATGGCTGGGAAAATGAC 
11b-HSD-2 CTGCTTCAAGACAGAGGCAGTGACT 
or 
CGCGGTGCTCATCACCGGTTGTGAC 
B2M TACTTGGATAACTGTGGTAATTCTA 
 
Table 2.1 TaqMan® Gene Expression Assay primer sequences. 
 
 
2.5.5 Rat Wound Healing PCR Array 
2.5.5.1 Reverse Transcription 
100 ng of the extracted RNA was reverse transcribed using the RT2 First Strand Kit 
(Qiagen). 2 µL of Buffer GE was added to the RNA, followed by RNase-free water 
to make a total reaction volume of 10 µL. The samples were incubated at 42oC for 5 
min and placed on ice for 1 min. This reaction was performed to eliminate genomic 
DNA contamination. 10 µL of reverse transcription mix (5X Buffer BCS 4 µL, 
Control P2 1 µL, RE3 RT Mix 2 µL and RNase-free water 3 µL) was added to the 
samples. After gentle mixing, the following conditions were run in a G-StormTM GSI 
thermal cycler: 42oC for 15 min followed by 95oC for 5 min. 91 µL RNase-free water 
was added, the samples were mixed by pipetting and placed on ice. 
 
2.5.5.2 RT2 RNA Quality Control PCR Array 
The quality of 12 RNA samples was simultaneously assessed using 6 µL of the final 
product of the reverse transcription reaction (2.5.5.1) in the RT2 RNA Quality Control 
PCR Array (Qiagen). 3 separate PCR component mixes for each RNA sample were 
prepared in a microcentrifuge tube as follows: 
 
Mix 1: 2X RT2 SYBR Green Mastermix (Qiagen) 75 µL, cDNA 6 µL and RNase-
free water 69 µL 
 
61 
Mix 2: 2X RT2 SYBR Green Mastermix 13 µL, 1/100 dilution of total input RNA 
1µL and RNase-free water 13 µL 
Mix 3: 2X RT2 SYBR Green Mastermix 30 µL and RNase-free water 30 µL 
 
The 3 mixes for each RNA sample were dispensed into the Rotor-Disc 100 ring 
provided as follows: 
 
Well Mastermix Control Type 
1 - 12 1 Beta Actin: Housekeeping Gene 
13 - 24 1 Hypoxanthine phosphoribosyltransferase 1: 
Housekeeping Gene 
25 - 36 1 Reverse transcription control 
37 - 48 1 Positive PCR control 
49 - 60 1 Rat genomic DNA contamination control 
61 - 72 2 No reverse transcription control 
73 - 84 3 Positive PCR control 
85 - 96 3 No template control 
97 - 100 Water Nil 
 
Table 2.2 Rotor-Disc 100 RT2 RNA quality control PCR array layout.  
Adapted from Qiagen product information (151). 
 
 
The ring was then sealed with Rotor-Disc Heat-Sealing Film and the Rotor-Disc Heat 
Sealer. A Corbett Rotor Gene 6000 Real Time PCR machine was used to run the 
samples under the following conditions: 1 cycle 10 min at 95oC, 40 cycles 10 s at 
95oC and 40 cycles 30 s at 60oC. 
 
2.5.5.3 RT2 Profiler Wound Healing Array 
A mastermix for each sample was prepared in a 5 mL tube as follows: 2X RT2 SYBR 
Green ROX FAST Mastermix (Qiagen) 1150 µL, cDNA from reverse transcription 
synthesis reaction 102 µL and RNase-free water 1048 µL. 20 µL was loaded into each 
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well of the array Rotor-Disc 100 rings provided. These are ready prepared with primer 
assays for 84 wound healing focused genes and 5 housekeeping genes. 7 wells contain 
a genomic DNA control, reverse transcription controls and a positive PCR control. 
The remaining 4 wells are empty, however mastermix is still loaded into these to 
ensure the ring is balanced. The arrays were then sealed with Rotor-Disc Heat-Sealing 
Film and the Rotor-Disc Heat Sealer. A Corbett Rotor Gene 6000 Real Time PCR 
machine was used to run the samples under the following conditions: 1 cycle 10 min 
at 95oC, 40 cycles 15 s at 95oC and 40 cycles 30 s at 60oC. 
 
2.5.6 Data Analysis 
Rotor-Gene Q Software Version 2.3 was used to analyze the PCR results (2.5.4 and 
2.5.5) and determine threshold cycle (CT) values for each well. The standard curve 
method for relative quantification of gene expression was utilized (152). 
 
Relative quantification    = (Efficiency Gene of interest)DCT(Gene of Interest) 
    (Efficiency Reference Gene)DCT(Reference Gene) 
 
To analyse the RT2 Profiler Wound Healing Array, the CT values for each primer 
assay for each sample were compiled in one Microsoft Excel file. Samples were 
assigned to either control or test groups. This was uploaded to Qiagen’s data analysis 
centre https://www.qiagen.com/gb/shop/genes-and-pathways/data-analysis-center-
overview-page/?akamai-feo=off. This web based portal calculates fold 
change/regulation using the DDCT method (DCT is calculated between the gene of 
interest and an average of the selected reference genes, followed by DDCT calculations 
(DCT (Test Group) – DCT (Control Group)). Fold change is then calculated using the 
2-DDCT formula. 
 
Housekeeping genes manually selected were B2M, hypoxanthine 
phosphoribosyltransferase 1, LDH A and ribosomal protein lateral stalk subunit P1. 
The fold regulation cut off was set to 2 (fold regulation represents fold-change in a 
biologically relevant way such that values greater than one indicate an upregulation 
and values less than one indicate a downregulation). A p value cut off was set at 0.05 
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(calculated within the portal based on a Student’s t-test of the replicate 2-D CT values 
for each gene in the control group and treatment groups). 
 
2.6 Histology and Immunohistochemistry 
Tissues from wound healing experiments were stored in 70% ethanol (VWR 
International Ltd) and processed by Professor Michael Sheaff and Ismail Bulut of 
Barts Health National Health Service Trust. The tissues were embedded in paraffin 
overnight using the Tissue-Tek VIP 6 AI Vacuum Infiltration Processor, Sakura, The 
Netherlands and 3 µm sections cut on a rotary microtome (Lecia RM2235, Leica 
Biosystems, Milton Keynes UK). Sections were then de-waxed, rehydrated and 
stained with Hematoxylin and Eosin (Vector Laboratories. Peterborough, UK).  
 
Immunohistochemistry was performed using the Vectastain®Elite®ABC HRP Kit, 
(Peroxidase, Universal), R.T.U (Ready to Use) as well as DAB Peroxidase (HRP) 
Substrate Kit (with Nickel), 3,3’-diaminobenzidine and counterstained with 
Hematoxylin (all from Vector Laboratories). 11b-HSD-1 antibody (Aviva Systems 
Biology) was used in 1:100 dilution with a 1 hour incubation period. Slides were then 
dehydrated, cleared and mounted using the Tissue-Tek Film Automated Cover 
Slipper (Sakura). 
 
A second set of prepared slides were incubated with Picro-sirius red (Sigma Aldrich) 
for 1 hour after staining cell nuclei with Weigert’s Hematoxylin (Sigma Aldrich) for 
8 minutes. After washing in acidified water and drying, slides were dehydrated, 
cleared and mounted as above. 
 
Professor Sheaff used the Aperio ImageScope Pathology Slide Viewing Software 
(Leica Biosystems) to review and analyse the slides prepared. 
 
2.7 Statistical Analysis 
Statistical analysis was completed using GraphPad Prism 8.0 software (San Diego, 
California, USA).  Data is presented as median with 95% Confidence Interval (CI) 
for non-parametric unpaired data. If comparisons were made between only 2 groups 
the Mann-Whitney U test was employed. If more than 2 groups were analysed 
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together the Kruskal Wallis test with Dunn’s multiple comparison test (between 
predefined groups) was performed. Two-way Analysis of Variance (ANOVA) was 
utilized to determine whether there was an interaction between the two independent 
variables on the dependent variable (for example the effect of drug concentration and 
time on final cortisol concentration). An extension of this, when one of the variables 
was a repeated measure was employed for analysing scratch assay data (mixed effects 
model with Geisser-Greenhouse correction and Dunnett’s multiple comparison test). 
A p value of < 0.05 was considered statistically significant. 
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CHAPTER 3 
In vitro Models of Wound Healing in Uraemia 
  
 
66 
3.1 Introduction 
Skin is a major extra-adrenal organ for steroid production (43, 67, 153, 154). Several 
steroidogenic enzymes and regulators have already been described within the skin 
including the GC regulators 11b-HSD-1 and 11b-HSD-2 (54, 60, 65-67, 73, 91). The 
localisation and activity of these GC regulators have also been described in aged skin 
(92, 93). As the uraemic state has been postulated as a state of accelerated ageing (6, 
155), we studied these enzymes in uraemic skin to ascertain whether similarities exist.  
 
To investigate the changes of expression or activity of 11b-HSD-1 and 11b-HSD-2 
in skin in renal failure, 2 cell types found in the dermis and epidermis (HDFs and 
HEKs) were studied. Due to inherent differences in function as well as localisation, 
each type could behave differently in response to stimulation. In this study, both were 
cultured separately in monolayers to investigate the effect of two uraemic toxins, IS 
and PC (Sigma-Aldrich) on cell survival and growth as well as looking at changes in 
expression of our enzymes of interest. A surrogate measure for 11b-HSD-1 reductase 
activity, cortisol production was measured via ELISA (Bio-Techne). 
 
Emodin (Sigma-Aldrich), a compound which has previously been shown to be a 
specific inhibitor of 11b-HSD-1 (105-109) was also studied in these cell types to 
ascertain whether a beneficial effect in healing could be observed. 
 
The scratch wound assay is felt to be a simple, reproducible and cost effective assay 
to study wound healing in vitro by analysing cell migration across a wound as well as 
cell-cell interactions (156-158). This model has been successfully used in healing 
studies in various cell types for over 25 years (158, 159).  Anderson et al. employed 
scratch assays in confluent monolayers of two renal tubular epithelial cell lines to 
study mechanisms of recovery from mechanical injury. They studied different growth 
platforms such as fibronectin and collagen as well as the effects addition of EGF, 
TGF-b1 or various interleukins to wounds would have (159).  On this basis, an in 
vitro scratch assay was employed to study the effects of IS, PC and emodin on healing. 
Utilising the JuLITM Stage real time automated cell imager system (from Cambridge 
Bioscience, Cambridge UK) enabled the visualisation of cell migration across the 
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wounded area over a defined period. Images were acquired at the start and at regular 
intervals to calculate the rate of cell migration. 
 
3.2 Results 
HDFs or HEKs (Fisher Scientific) were cultured in T25 flasks until 70% confluent as 
described in section 2.1.2 and then serum starved overnight. To investigate the 
possible effect of the uraemic toxins IS and PC on 11b-HSD-1 and 11b-HSD-2 
protein expression, either IS or PC were added to cultures in a range of concentrations 
for 1, 3, 16 or 48 h (section 2.1.3). Cells were lysed (section 2.1.6) to extract protein, 
which was semi-quantified and resolved on western blots (section 2.3).   
 
To investigate the inhibitory effect of emodin on 11b-HSD-1 protein expression, 
emodin was added to cultures at a range of concentrations for 1, 3, 16 or 48 h (section 
2.1.4) before cells were lysed to extract protein, which was semi-quantified and 
resolved on western blots.   
 
3.2.1 Western Blotting 
3.2.1.1 Western Blots of Protein Extracts from HDFs 
Figures 3.1 and 3.2 demonstrate that HDFs do express both 11b-HSD-1 and 11b-
HSD-2 proteins, however there is no discernible change in either enzyme’s protein 
expression in response to the concentrations of IS or PC used at the time points 
investigated. 
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Figure 3.1 Expression of 11b-HSD-1 and 11b-HSD-2 in HDFs cultured with IS. 
HDF cells were grown to 70% confluency in T25 flasks, with IS added to achieve 
concentrations of 0, 25, 50 or 100 µg/mL for 1, 3, 16 or 48 h. Protein bands from cell 
lysates were resolved by western blotting. Bands immunoreactive to antibodies for 
11b-HSD-1 at 32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. 
Images representative of n = 3 per each western blot. 
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Figure 3.2 Expression of 11b-HSD-1 or 11b-HSD-2 in HDFs cultured with PC. 
HDF cells were grown to 70% confluency in T25 flasks with PC added to achieve 
concentrations of 0, 10, 25 or 50 µg/mL for 1, 3, 16 or 48 h. Protein bands from cell 
lysates were resolved by western blotting. Bands immunoreactive to antibodies for 
11b-HSD-1 at 32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. 
Images representative of n = 3 per each western blot. 
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Figure 3.3 demonstrates that HDF cultures demonstrate no change in either 11b-HSD-
1 or 11b-HSD-2 protein expression in response to the concentrations of emodin used 
at the time points investigated. 
 
 
 
Figure 3.3 Expression of 11b-HSD-1 or 11b-HSD-2 in HDFs cultured with 
emodin. HDF cells were grown to 70% confluency in T25 flasks, with emodin added 
to achieve concentrations of 0, 20, 50 or 100 µM for 1, 3, 16 or 48 h. Protein bands 
from cell lysates were resolved by western blotting. Bands immunoreactive to 
antibodies for 11b-HSD-1 at 32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa 
are shown. Images representative of n = 3 per each western blot. 
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3.2.1.2 Western Blots of Protein Extracts from HEKs 
Figures 3.4 and 3.5 demonstrate that HEKs do express both 11b-HSD-1 and 11b-
HSD-2 proteins, however there is no change in either enzyme’s protein expression in 
response to the concentrations of IS or PC used at the time points investigated. A 
second band was detected (at approximately 46 kDa) only on western blots incubated 
with 11b-HSD-2 of IS experiments at 1 and 3 h as well as all 4 time points of PC 
experiments. Thurston et al. also demonstrated two bands on western blots differing 
by 2 kDa, postulating that the larger detected protein was a form of 11b-HSD-2 that 
had been post-translationally modified (160).  This would be a feasible explanation 
for the two bands seen in these blots as well. Only one band was detected when 
membranes were re-probed for GAPDH. 
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Figure 3.4 Expression of 11b-HSD-1 or 11b-HSD-2 in HEKs cultured with IS. 
HEK cells were grown to 70% confluency in T25 flasks, with IS added to achieve 
concentrations of 0, 25, 50 or 100 µg/mL for 1, 3, 16 or 48 h. Protein bands from cell 
lysates were resolved by western blotting. Bands immunoreactive to antibodies for 
11b-HSD-1 at 32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. 
Images representative of n = 3 per each western blot. 
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Figure 3.5 Expression of 11b-HSD-1 or 11b-HSD-2 in HEKs cultured with PC. 
HEK cells were grown to 70% confluency in T25 flasks, with PC added to achieve 
concentrations of 0, 10, 25 or 50 µg/mL for 1, 3, 16 or 48 h. Protein bands from cell 
lysates were resolved by western blotting. Bands immunoreactive to antibodies for 
11b-HSD-1 at 32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. 
Images representative of n = 3 per each western blot. 
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Figure 3.6 demonstrates that HEK cultures demonstrate no change in either 11b-
HSD-1 or 11b-HSD-2 protein expression in response to the concentrations of emodin 
used at the time points investigated. At 1 and 3 h a double band is again noted on 
western blots incubated with 11b-HSD-2, this time at lower molecular weight than 
expected, most likely due to degraded samples. The second band was not detected 
when re-probed for GAPDH. 
 
 
 
Figure 3.6 Expression of 11b-HSD-1 or 11b-HSD-2 in HEKs cultured with 
emodin. HEK cells were grown to 70% confluency in T25 flasks, with emodin added 
to achieve concentrations of 0, 20, 50 or 100 µM for 1, 3, 16 or 48 h. Protein bands 
from cell lysates were resolved by western blotting. Bands immunoreactive to 
antibodies for 11b-HSD-1 at 32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa 
are shown. Images representative of n = 3 per each western blot. 
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3.2.2 LDH Assays 
LDH assays (Roche Diagnostics Limited) were performed on media removed from 
T25 flasks of all HDF and HEK experiments with IS, PC and emodin at 1, 3, 16 and 
48 h as described in section 2.1.5. The cell culture media used for both cell lines 
contained pyruvate, which is known to interfere with LDH activity (in an inhibitory 
fashion). Minimal activity could be detected that could not reliably be attributed to 
the compounds being investigated, hence this data has been excluded. In addition, the 
formazan product measured in this assay has an orange colour. Likewise, the 
formulation of emodin used in these experiments had orange colouration which 
interfered with the accurate detection of true LDH activity (data not shown).  
 
3.2.3 Cortisol ELISA 
Cortisol ELISA (Bio-Techne) was performed on 100 µL media removed from T25 
flasks of all HDF and HEK experiments conducted with IS, PC and emodin at 1, 3, 
16 and 48 h as described in section 2.4. Cortisol concentrations were corrected for 
total protein concentration of the cell lysates from the flask, as ascertained by a BCA 
assay (Fisher Scientific Ltd). Cortisol concentrations from HDF experiments were not 
reliably detectable within the range of this ELISA (concentrations were too low) even 
when media samples obtained from T25 flasks were pooled (data not shown). 
  
 
76 
   
 
Figure 3.7 Cortisol concentration of HEKs cultured with IS. HEK cells were 
grown to 70% confluency in T25 flasks with IS added to achieve concentrations of 0, 
25, 50 and 100 µg/mL for 1, 3, 16 or 48 h. 100 µL of the culture medium was used in 
a cortisol ELISA. The detected cortisol concentration was corrected to the protein 
concentration of the cell lysates as determined by a BCA assay, n = 3 per IS 
concentration at each time point. Data shown as median + 95% CI analysed by 2-way 
ANOVA. 
 
 
A two-way ANOVA was conducted that examined the effect of IS concentration and 
time on cortisol concentrations. There was no statistically significant interaction 
between the effects of IS concentration and time F(9,32) = 0.063, p > 0.999.  
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Figure 3.8 Cortisol concentration of HEKs cultured with PC. HEK cells were 
grown to 70% confluency in T25 flasks with PC added to achieve concentrations of 
0, 10, 25 and 50 µg/mL for 1, 3, 16 or 48 h. 100 µL of the culture medium was used 
in a cortisol ELISA. The detected cortisol concentration was corrected to the protein 
concentration of the cell lysates as determined by a BCA assay, n = 3 per PC 
concentration at each time point. Data shown as median + 95% CI analysed by 2-way 
ANOVA. 
 
 
A two-way ANOVA was conducted that examined the effect of PC concentration and 
time on cortisol concentrations produced by HEK cells. There was no statistically 
significant interaction between the effects of PC concentration and time F(9,36) = 
0.44, p = 0.907.  
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Figure 3.9 Cortisol concentration of HEKs cultured with emodin. HEK cells were 
grown to 70% confluency in T25 flasks with emodin added to achieve concentrations 
of 0, 20, 50 and 100 µM for 1, 3, 16 or 48 h. 100 µL of the culture medium was used 
in a cortisol ELISA. The detected cortisol concentration was corrected to the protein 
concentration of the cell lysates as determined by a BCA assay, n = 3 per emodin 
concentration at each time point. Data shown as median + 95% CI analysed by 2-way 
ANOVA. 
 
 
A two-way ANOVA was conducted that examined the effect of emodin concentration 
and time on cortisol concentrations produced by HEK cells. There was no statistically 
significant interaction between the effects of emodin concentration and time F(9,32) 
= 0.18, p = 0.995. 
 
3.2.4 MTS Assays 
HDFs or HEKs were cultured in 96 well plates prior to the addition of IS, PC or 
emodin over the range of concentrations used in experiments conducted in T25 flasks 
(section 2.1.3 and 2.1.4). After 48 h of incubation, a MTS assay (Promega) was 
completed as described in 2.1.7. These experiments were also carried out in cells that 
had been serum starved overnight prior to the addition of IS, PC or emodin as 
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components of undefined FBS could interact with the MTS assay (causing increased 
production of the formazan product) (161). 
 
3.2.4.1 MTS Assays in HDFs 
Upon addition of 100 µg/mL of IS, a significantly reduced absorbance at 490nm and 
hence reduced MTS activity was noted as compared to control cells. This difference 
was noted whether the HDFs were serum starved or not (Figure 3.10 A and B). In 
addition, when HDFs were serum starved with 50 µg/mL of IS, significantly reduced 
MTS activity was also observed.  
 
 
 
Figure 3.10 MTS activity of HDFs cultured with IS; with FBS (A) or serum 
starved overnight (B). HDF cells were cultured in 96 well plates with IS added to 
achieve concentrations of 0, 25, 50 and 100 µg/mL. After 48 hours, a MTS assay was 
performed. N = 20 per IS concentration, n = 4 per negative control (no cells). Data 
represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple 
comparisons test. * denotes significance level p < 0.05 and ** p < 0.01. 
 
 
  
0 25 50 10
0
0.0
0.5
1.0
1.5
**
IS Concentration (µg/mL)
A
b
so
rb
a
n
ce
 a
t 
4
9
0
n
m
0 25 50 10
0
0.0
0.5
1.0
1.5
**
*
IS Concentration (µg/mL)
A
b
so
rb
a
n
ce
 a
t 
4
9
0
n
m
A B
 
80 
No significant differences in MTS activity were noted when PC was added to HDFs 
in the fed state (Figure 3.11 A). However, when HDFs were serum starved, treatment 
with 10, 25 or 50 µg/mL of PC seemed to significantly increase MTS activity (Figure 
3.11 B). These results are likely artefactual as the PC 0 µg/mL MTS activity is lower 
than expected. 
 
 
 
Figure 3.11 MTS activity of HDFs cultured with PC; with FBS (A) or serum 
starved overnight (B). HDF cells were cultured in 96 well plates with PC added to 
achieve concentrations of 0, 10, 25 and 50 µg/mL. After 48 hours, a MTS assay was 
performed. N = 20 per PC concentration, n = 4 per negative control (no cells). Data 
represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple 
comparisons test. * denotes significance level p < 0.05 ** p < 0.01 and *** p < 0.001. 
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When treating HDFs in the serum starved and fed state with emodin, significantly 
reduced MTS activity was seen at all concentrations (Figures 3.12 A and B) 
 
 
 
Figure 3.12 MTS activity of HDFs cultured with emodin; with FBS (A) or serum 
starved overnight (B). HDF cells were cultured in 96 well plates with emodin added 
to achieve concentrations of 0, 20, 50 and 100 µM. After 48 h, a MTS assay was 
performed. N = 20 per emodin concentration, n = 4 per negative control (no cells). 
Data represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s 
multiple comparisons test. * denotes significance level p < 0.05 and *** p < 0.001. 
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3.2.4.2 MTS Assays in HEKs 
Upon addition of 100 µg/mL of IS, a significantly reduced absorbance at 490nm and 
hence reduced MTS activity was noted as compared to control cells (Figure 3.13 A). 
This difference did not retain significance when the cells were serum starved (Figure 
3.13 B). 
 
 
 
Figure 3.13 MTS activity of HEKs cultured with IS; with FBS (A) or serum 
starved overnight (B). HEK cells were cultured in 96 well plates with IS added to 
achieve concentrations of 0, 25, 50 and 100 µg/mL. After 48 hours, a MTS assay was 
performed. N = 20 per IS concentration, n = 4 per negative control (no cells). Data 
represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple 
comparisons test. *** denotes significance level p < 0.001. 
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Upon addition of 25 or 50 µg/mL PC to HEKs in the fed state, significantly greater 
MTS activity was detected. No significant differences in MTS activity were noted 
when PC was added to HEKs in the serum starved state (Figure 3.14 B). 
 
 
 
Figure 3.14 MTS activity of HEKs cultured with PC; with FBS (A) or serum 
starved overnight (B). HEK cells were cultured in 96 well plates with PC added to 
achieve concentrations of 0, 10, 25 and 50 µM. After 48 hours, a MTS assay was 
performed. N = 20 per PC concentration, n = 4 per negative control (no cells). Data 
represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple 
comparisons test. *** denotes significance level p < 0.001. 
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When treating HEKs in the serum starved and fed state with emodin, significantly 
reduced MTS activity was seen at all concentrations (Figures 3.15 A and B). 
 
 
Figure 3.15 MTS activity of HEKs cultured with emodin; with FBS (A) or serum 
starved overnight (B). HEK cells were cultured in 96 well plates with emodin added 
to achieve concentrations of 0, 20, 50 and 100 µM. After 48 hours, a MTS assay was 
performed. N = 20 per emodin concentration, n = 4 per negative control (no cells). 
Data represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s 
multiple comparisons test. *** denotes significance level p < 0.001. 
 
 
3.2.5 Scratch Wound Healing Assays 
HDFs or HEKs were cultured to 70% confluency in 12 well non-coated plates. A 
scratch was made across the well with a 20 µL sterile pipette tip before the old culture 
media was removed and replaced with solutions of IS, PC or emodin across the range 
of concentrations used in T25 flask experiments (section 2.1.3 and 2.1.4). Healing of 
the scratch wound was measured by the JuLITM Stage cell imager over a predefined 
period. Experiments were also carried out in cells that had been serum starved 
overnight before scratching and addition of experimental solutions (see section 2.1.8). 
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3.2.5.1 Scratch Assays in HDFs 
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Figure 3.16 Scratch assay in HDFs cultured with PC. HDF cells were grown to 
70% confluency in 12 well plates. After a scratch was made with a 20 µL pipette tip, 
PC was added to achieve concentrations of 0, 10, 25 and 50 µg/mL. Wound healing 
over 24 h was measured by the JuLITM Stage cell imager, n = 3 per PC concentration. 
Data represented as median + 95% CI analysed by mixed effects model with Geisser-
Greenhouse correction and Dunnett’s multiple comparison test. 
 
 
A mixed effects model with Greenhouse-Geisser correction showed a statistically 
significant interaction between PC concentration and time of wound healing in HDFs, 
F(66,176) = 5.597, p <0.001. There was a significant main effect of time F(1.618, 
12.94) = 140.7, p <0.001 suggesting that time is the influential factor (Figure 3.16). 
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Figure 3.17 Scratch assay in serum starved HDFs cultured with IS. HDF cells 
were grown to 70% confluency in 12 well plates before being serum starved 
overnight. After a scratch was made with a 20 µL pipette tip, IS was added to culture 
medium containing no FCS or antibiotics to achieve concentrations of 0, 25, 50 and 
100 µg/mL. Wound healing over 24 hours was measured by the JuLITM Stage cell 
imager, n = 2 per IS concentration. Data represented as median + 95% CI analysed 
by mixed effects model with Geisser-Greenhouse correction and Dunnett’s multiple 
comparison test. 
 
 
A mixed effects model with Greenhouse-Geisser correction showed no statistically 
significant interaction between IS concentration and time of wound healing in serum 
starved HDFs, F(33,44) = 0.488, p = 0.983 (Figure 3.17). 
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3.2.5.2 Scratch Assays in HEKs 
 
 
 
Figure 3.18 Scratch assay in HEKs cultured with IS. HEK cells were grown to 
70% confluency in 12 well plates. After a scratch was made with a 20 µL pipette tip, 
IS was added to achieve concentrations of 0, 25, 50 and 100 µg/mL. Wound healing 
over 24 hours was measured by the JuLITM Stage cell imager, n = 3 per IS 
concentration. Data represented as median + 95% CI analysed by mixed effects model 
with Geisser-Greenhouse correction and Dunnett’s multiple comparison test. 
 
 
A mixed effects model with Greenhouse-Geisser correction showed no statistically 
significant interaction between IS concentration and time of wound healing in HEKs, 
F(66,176) = 0.824, p = 0.817 (Figure 3.18). 
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Figure 3.19 Scratch assay in serum starved HEKs cultured with IS. HEK cells 
were grown to 70% confluency in 12 well plates before being serum starved 
overnight. After a scratch was made with a 20 µL pipette tip, IS was added to culture 
medium containing no FCS or antibiotics to achieve concentrations of 0, 25, 50 and 
100 µg/mL. Wound healing over 24 hours was measured by the JuLITM Stage cell 
imager, n = 3 per IS concentrations except n = 2 for 50 µg/mL. Data represented as 
median + 95% CI analysed by mixed effects model with Geisser-Greenhouse 
correction and Dunnett’s multiple comparison test. 
 
 
A mixed effects model with Greenhouse-Geisser correction showed a statistically 
significant interaction between IS concentration and time on wound healing in serum 
starved HEKs, F(69,161) = 1.657, p = 0.005. There was a significant main effect of 
time F(2.009, 14.07) = 3.139, p <0.001suggesting that time was the influential factor 
(Figure 3.19). Within Dunnett’s multiple comparison test, at 3 h there was a 
significant difference in healing between control cells and those exposed to 25 µg/mL 
and 100µg/mL. This difference was no longer significant by the 4th hour. At 11 h, 15 
h and 16 h post wounding there was a significant difference in healing between those 
cells exposed to 100 µg/mL of IS and control cells which had disappeared by 17 h 
(Figure 3.19). 
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Figure 3.20 Scratch assay in HEKs cultured with PC. HEK cells were grown to 
70% confluency in 12 well plates. After a scratch was made with a 20 µL pipette tip, 
PC was added to achieve concentrations of 0, 10, 25 and 50 µg/mL. Wound healing 
over 24 h was measured by the JuLITM Stage cell imager, n = 3 per PC concentration. 
Data represented as median + 95% CI analysed by mixed effects model with Geisser-
Greenhouse correction and Dunnett’s multiple comparison test. 
 
 
A mixed effects model with Greenhouse-Geisser correction showed a statistically 
significant interaction between PC concentration and time on wound healing in 
HEKs, F(69,182) = 11.570, p <0.001. There was a significant main effect of time 
F(3.307,26.17) = 411.3, p <0.001 and a significant main effect of PC concentration 
F(3,8) = 72.50, p < 0.001 (Figure 3.20). Within Dunnett’s multiple comparison test, 
increasing PC concentration had a significant effect on percentage wound healing in 
HEK cells when compared to control cells between 3 and 7 hours for all PC 
experimental concentrations (10, 25 and 50 µg/mL) and inexplicably at 15, 17 and 21 
h. HEK cells cultured with 50 µg/mL PC demonstrated consistent significant 
differences in healing when compared to control cells from 3 through to 24 h (Figure 
3.20). Further investigation of the effect of PC on wound healing in HEKs would be 
indicated. 
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Figure 3.21 Scratch assay in serum starved HEKs cultured with PC. HEK cells 
were grown to 70% confluency in 12 well plates before being serum starved 
overnight. After a scratch was made with a 20 µL pipette tip, PC was added to culture 
medium containing no FCS or antibiotics to achieve concentrations of 0, 10, 25 and 
50 µg/mL. Wound healing over 24 h was measured by the JuLITM Stage cell imager, 
n = 2 per PC concentration except n =1 for 50 µg/mL. Data represented as median + 
95% CI analysed by mixed effects model with Geisser-Greenhouse correction and 
Dunnett’s multiple comparison test. 
 
 
A mixed effects model with Greenhouse-Geisser correction showed a statistically 
significant interaction between PC concentration and time of wound healing in serum 
starved HEKs, F(69,69) = 7.699, p <0.001. There was a significant main effect of 
time F(1.552, 4.655) = 132.2, p <0.001 and a significant main effect of PC 
concentration F(3,3) = 12.24, p = 0.034 (Figure 3.21). Further studies are warranted 
given the small numbers investigated. 
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Figure 3.22 Scratch assay in HEKs cultured with emodin. HEK cells were grown 
to 70% confluency in 12 well plates. After a scratch was made with a 20 µL pipette 
tip, emodin was added to achieve concentrations of 0, 20, 50 and 100 µM. Wound 
healing over 24 h was measured by the JuLITM Stage cell imager, n = 3 per emodin 
concentration except n = 1 for 100 µM. Data represented as median + 95% CI 
analysed by mixed effects model with Geisser-Greenhouse correction and Dunnett’s 
multiple comparison test. 
 
 
A mixed effects model with Greenhouse-Geisser correction showed no statistically 
significant interaction between emodin concentration and time on wound healing in 
HEKs, F(69,138) = 0.716, p = 0.938 (Figure 3.22). 
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Figure 3.23 Scratch assay in serum starved HEKs cultured with emodin. HEK 
cells were grown to 70% confluency in 12 well plates before being serum starved 
overnight. After a scratch was made with a 20 µL pipette tip, emodin was added to 
culture medium containing no FCS or antibiotics to achieve concentrations of 0, 20, 
50 and 100 µM. Wound healing over 24 h was measured by the JuLITM Stage cell 
imager, n = 3 per emodin concentration. Data represented as median + 95% CI 
analysed by mixed effects model with Geisser-Greenhouse correction and Dunnett’s 
multiple comparison test. 
 
 
A mixed effects model with Greenhouse-Geisser correction showed a statistically 
significant interaction between emodin concentration and time on wound healing in 
serum starved HEKs, F(69,184) = 2.002, p < 0.001. There was a significant main 
effect of time F(1.353, 10.82) = 113.3, p <0.001 (Figure 3.23). 
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Scratch assays were also performed with concentrations of IS that were much greater 
than used thus far (100, 200 and 400 µg/mL) to determine whether healing would be 
adversely affected (Figure 3.24 and 3.25). 
 
 
 
Figure 3.24 Scratch assay in HEKs cultured with high concentration IS. HEK 
cells were grown to 70% confluency in 12 well plates. After a scratch was made with 
a 20 µL pipette tip, IS was added to achieve concentrations of 0, 100, 200 and 400 
µg/mL. Wound healing over 12 h was measured by the JuLITM Stage cell imager, n = 
3 per IS concentration. Data represented as median + 95% CI analysed by mixed 
effects model with Geisser-Greenhouse correction and Dunnett’s multiple 
comparison test. 
 
 
A mixed effects model with Greenhouse-Geisser correction showed no statistically 
significant interaction between higher IS concentration and time on wound healing in 
HEKs, F(33,88) = 1.137, p = 0.312 (Figure 3.24). 
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Figure 3.25 Scratch assay in serum starved HEKs cultured with high 
concentration IS. HEK cells were grown to 70% confluency in 12 well plates before 
being serum starved overnight. After a scratch was made with a 20 µL pipette tip, IS 
was added to culture medium containing no FCS or antibiotics to achieve 
concentrations of 0, 100, 200 and 400 µg/mL. Wound healing over 12 hours was 
measured by the JuLITM Stage cell imager, n = 3 per IS concentration. Data 
represented as median + 95% CI analysed by mixed effects model with Geisser-
Greenhouse correction and Dunnett’s multiple comparison test. 
 
 
A mixed effects model with Greenhouse-Geisser correction showed a statistically 
significant interaction between higher IS concentration and time of wound healing in 
serum starved HEKs, F(33,88) = 2.028, p = 0.005. There was a significant main effect 
of time F(1.376, 11.0) = 289.7, p <0.001 (Figure 3.25). 
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Control – 0 hours     
 
 
Control – 12 hours 
 
 
Control – 24 hours 
 
Treated – 0 hours 
 
 
Treated – 12 hours 
 
 
Treated – 24 hours  
Figure 3.26 In vitro wound healing in HDFs. Representative images shown for 
control and 1 treatment concentration at 0, 12 and 24 h after wounding. 
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Control – 0 hours 
 
 
Control – 12 hours 
 
 
Control – 24 hours 
 
Treated – 0 hours 
 
 
Treated – 12 hours 
 
 
Treated – 24 hours
Figure 3.27 In vitro wound healing in HEKs. Representative images shown for 
control and 1 treatment concentration at 0, 12 and 24 hours after wounding. 
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3.3 Discussion 
Whilst culturing HDF and HEK cells for experiments, several difficulties were 
encountered. The cells were found to be sensitive to Trypsin-EDTA (Sigma-Aldrich) 
even after the briefest exposure to minimal volumes needed for successful passaging. 
The cells would recover and grow poorly after this contact. Initially, Trypsin 
Neutralizing Solution (Fisher Scientific Ltd) was used in equivalent quantities to 
Trypsin-EDTA after cells had detached from the flask to mitigate against this with 
some improvement. Ultimately, TrypLE™ Express Enzyme 1X (Fisher Scientific 
Ltd) was used to detach cells followed by Trypsin Neutralizing Solution in equal 
quantities. 
 
Specific culture media was required for each cell type. At the outset, Human 
Fibroblast Basal Medium with antibiotic and Human Fibroblast Growth Supplement 
(all from Cellworks, supplied by Caltag Medsystems, Buckingham, UK) was used 
with HDFs and Keratinocyte Medium with antibiotic and Keratinocyte Growth 
Supplement (all from ScienCell, supplied by Caltag Medsystems, Buckingham, UK) 
used for HEKs. Both media were found to be photosensitive and heat labile in our 
hands which affected cell proliferation. After this discovery, the use of water baths 
was avoided and media bottles were left to equilibrate to room temperature, protected 
from light by a cover prior to use. After an initial set of experiments had been 
completed, I recognized that the composition of complete media was unknown and 
may contain steroid hormones that could affect the expression or activity of 11b-
HSD-1 and 11b-HSD-2. The manufacturers were contacted to try to define the 
constituents. Cellworks reported this information was proprietary and they could not 
assist us whilst ScienCell confirmed the presence of hydrocortisone 0.5 µg/mL and 
bovine pituitary extract which was undefined. Experiments were thus repeated using 
openly defined media; DMEM with FBS and antibiotics (Sigma-Aldrich) and Gibco 
EpilifeTM medium with 60 µM calcium (Fisher Scientific Ltd) and provided 
supplement Human Keratinocyte Growth Supplement (HKGS).  Prior to performing 
experiments with toxins or inhibitors of interest, the cells were starved of the 
supplements overnight (FBS, antibiotics for HDFs and HKGS for HEKs) and 
experiments conducted in non-supplemented media. This was done to bring all cells 
into the same phase of the cell cycle and to control for the multitude of both protective 
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or destructive effects the various constituents of undefined FBS/supplements could 
have on 11b-HSD-1 and 11b-HSD-2 expression and activity. As IS and PC are both 
protein bound compounds, the true effect of the toxins may not have been seen in 
serum starved conditions with the concentrations of toxins used here. In retrospect, 
all experiments would have been conducted firstly with the addition of toxin in 
conditions with and without serum. If a difference was detected, experiments could’ve 
been repeated with increasing concentrations of serum and titrated doses of toxin. 
 
Western blotting demonstrates that HDFs and HEKs do express both 11b-HSD-1 and 
11b-HSD-2 proteins. In response to uraemic toxins in isolation, the expression of 
neither enzyme changes at the doses used or in the time frame studied. Although these 
doses are in the range found in patients with CKD (129) the published concentrations 
in CKD were ascertained from serum not skin samples. Thus far, it is unclear whether 
IS or PC have a direct pathogenic effect in skin or indeed whether their metabolism 
or toxicity is diminished as the skin is considered a peripheral organ. Studying cells 
in a monolayer may be artificial in comparison to in vivo, where in the epidermis cells 
are stacked, interacting closely with each other (14). Epidermal cells undergo a 
gradated differentiation response (16) which may alter the cells’ responsiveness to an 
insult from IS or PC and indeed may alter their ability to express 11b-HSD-1 and 
11b-HSD-2.  
 
No firm conclusions can be drawn with regards to 11b-HSD-1 activity in response to 
IS, PC or emodin over the period studied from the associated cortisol ELISA 
performed. Detecting cortisol from cell culture supernatants via ELISA was 
challenging. Experiments with IS, PC or emodin were initially conducted in 6-well 
plates with 100 µL of the total 1.5 mL media used in the ELISA. However, cortisol 
concentrations were undetectable with this method. Aliquots of supernatants from 
several 6-well experiments were pooled and the ELISA repeated, to no avail. All 
experiments were repeated in T25 flasks to increase the ratio of cells to media. 
Cortisol concentrations were finally measurable (range of assay 0.030 -0.111 ng/mL) 
consistently for HEK cells but unfortunately not for HDFs. 11b-HSD-1 is known to 
possess bidirectional properties (70, 80). Although oxoreductase activity (converting 
cortisone to cortisol) has previously been shown to predominate in certain intact cell 
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systems (80) it is unclear whether reductase or dehydrogenase activity prevails in 
HDF and HEK cultures at baseline and whether IS, PC or emodin influence the 
directionality of the enzyme. To ascertain this information, cortisone and cortisol 
concentrations would need to be assayed simultaneously. The use of tritiated tracers 
has been shown to be useful in similar situations (162, 163). Unfortunately, this was 
not available to our laboratory during this study. In retrospect, the use of a positive 
control in these experiments (a promoter of cortisol synthesis such as ACTH or 
CYP11B1 and a plentiful supply of NADPH) may have assisted in teasing out this 
information. 
 
The aim of using LDH and MTS assays was to ascertain whether HDF and HEK cells 
were viable over the course of experiments with IS, PC and emodin. As previously 
described, LDH assays were non-contributory as cell culture media contained 
pyruvate, which is known to interfere with LDH activity (164). Low levels of LDH 
activity were unreliably detected, which could not fully exclude this confounding 
factor. 
 
The MTS assays performed for 48 h did not provide consistent data. HDF and HEK 
cells treated with 100 µg/mL IS in complete media demonstrated significantly 
reduced absorbance measurements at 490nm and hence MTS activity. This remained 
true for serum starved HDFs treated with 50 and 100 µg/mL IS but not serum starved 
HEKs. Astonishingly, PC at all concentrations in serum starved HDFs and at 25 and 
50 µg/mL in HEKs in complete media seemed to have a positive effect on MTS 
activity. These results need to be treated with caution due to the limitations of the 
assay; interactions with any compound with inherent reductive properties could alter 
the amount of formazan product made (165) as can composites of the culture medium 
such as the pH and glucose concentration (166, 167).  Additionally, the confluence of 
cells within the plate may alter the results obtained as contact inhibition of cells can 
change metabolic activity in a fashion that is non-linear to the number of cells present 
(thus altering absorbance in a non-predictable manner) (168). It is likely the orange 
colouration of emodin interfered with the colorimetric measurements obtained with 
HDFs and HEKs in both the LDH and MTS assays, hence cannot be relied upon to 
draw firm conclusions.  Specific 11b-HSD-1 inhibitors that were inexpensive and 
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opaque were not available. Furthermore, although cells may be viable the MTS assay 
does not enlighten us as to whether the cell phenotype has changed in response to the 
toxin exposure.  
 
Similarly, with scratch assays analysed by the JuLITM Stage cell imager no robust 
conclusions with regards to the effects of IS, PC or emodin on wound healing can be 
drawn (n = 3) although the results of HEK cells treated with PC show promise for 
further investigation as do higher concentrations of IS. Despite solubilisation in 
DMSO prior to addition to culture medium, emodin was observed to precipitate out 
in 12-well plates over time causing a foggy appearance that clouded the scratches 
made. It is doubtful that the programme software could have accurately corrected for 
this effect when reporting percentage wound healing. A known inhibitor of 
keratinocyte migration and subsequent wound healing called zaragozic acid A, a 
squalene synthetase inhibitor known to increase FPP concentrations or indeed FPP 
itself could be employed as a positive control in future scratch assays (51). 
 
Unfortunately, time was limited to fully utilise the inbuilt functions of the JuLITM 
Stage cell imager. Rates of healing are likely to differ for cells of different passages 
and at non-standardized confluency as well as in different sized vessels (for example 
a 24-well plate versus a 6-well plate). Plates coated with growth matrices such as 
collagen or fibronectin would provide a more true-to-life base to study wound healing 
as would co-culturing skin cells and performing scratch assays thereafter, although 
teasing apart contributions from each contributory cell culture may be arduous. 
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CHAPTER 4 
In vivo Wound Healing in a Rat Model of 
Uraemia 
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4.1 Introduction 
As observed in Chapter 3, HDF and HEK cells do express 11b-HSD-1 and 11b-HSD-
2, although their expression did not alter in vitro in response to simulated uraemia. 
The uraemic milieu is complex, although numerous compounds have been isolated 
and extensively studied (1, 169, 170), there are thought to be other toxins which have 
not yet been identified or their pathogenic effects fully described. Similarly, skin as 
an organ is a complex multi-layered structure incorporating several cell types which 
interact with each other and respond to noxious stimuli (11, 12, 15, 171). These 
interactions cannot be sufficiently replicated in a monolayer cell culture.  
 
Rodents have been successfully used to study wound healing (38, 93, 94, 128, 172). 
Mouse skin has a paucity of eccrine sweat glands that express 11b-HSD-2 (except in 
paw pad skin) unlike human skin where these glands are commonly found (92). 
Tiganescu et al. did not detect 11b-HSD dehydrogenase activity in wild type mouse 
skin explants following incubation with corticosterone but did detect dehydrogenase 
activity in human skin explants (92). As the findings from these experiments would 
ultimately be used to benefit human patients, mice were not the animal of choice in 
these studies. We have previously demonstrated the successful induction of renal 
impairment in two rat models (148). The adenine diet model has been chosen for these 
in vivo studies. The induction of renal impairment is rapid, reliable and reproducible. 
This model eliminates the inter and intra-operative variability associated with the SNx 
procedure as well as requiring no surgical skill or training to employ.  Additionally, 
post-operatively SNx rodents will be inflamed which will add a confounding factor 
to wound healing studies. In keeping with our laboratory group’s published success 
employing the adenine diet model in rats (148) and the 3R principles, the number of 
animals per group was intentionally kept as low as possible to enable sufficient 
sample collection for all the proposed experiments. No premature mortality was 
observed in these experiments. 
 
A specific inhibitor of 11b-HSD-1 (108, 109) was required which was non-toxic and 
cost effective in the quantities required. Carbenoxolone could not be used as it is 
known to inhibit both 11b-HSD-1 and 11b-HSD-2 (173, 174). Therefore, any 
differences seen in healing could not be clearly attributed to 11b-HSD-1. For these 
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reasons, emodin (Fluorochem Limited) was utilised in the in vivo experiments. 
Topical application was the preferred method of drug dosing to investigate a skin 
specific effect. Systemic dosing was also employed to guarantee dose delivery. Two 
different time points after wounding were chosen to see when potential wound healing 
effects would be found (day 3 and day 7). Tiganescu et al. demonstrated 10-fold 
greater 11b-HSD-1 mRNA expression at day 2 compared to unwounded control skin, 
which had reduced to 3-fold greater expression by day 4, returning to levels similar 
to those found in unwounded skin by day 8. Similar patterns were seen with 11b-
HSD-1 protein expression (94). 
 
Variables measured included serum and skin corticosterone concentrations (to 
determine the product of 11b-HSD-1 reductase enzyme activity and to find whether 
the results observed could be attributed solely to tissue specific or systemic 11b-HSD-
1 activity), percentage area of wound healing and rat weight. Western blotting was 
performed on skin tissue homogenates to ascertain the presence or absence of 11b-
HSD-1 and 11b-HSD-2. Following on from this, RNA extracted from tissue 
homogenates was utilised in PCR reactions to quantify the 11b-HSD-1 mRNA 
present. As additional molecules and pathways could be implicated in wound healing 
in uraemia, a wound healing array (Qiagen) was performed with the RNA samples to 
identify targets for further research. 
 
4.2 Results  
4.2.1 Rat Wound Healing 
20 male Wistar rats were used for initial experiments. 10 rats had uraemia induced by 
feeding a 0.75% adenine supplemented normal diet (SDS Diets) and the remaining 10 
rats were fed normal chow over 3 weeks and acted as controls.  Each animal 
underwent wounding as described on day 0 (section 2.2.3.1). After 3 days 5 uraemic 
and 5 control animals were culled. After 7 days, the remaining 5 uraemic and 5 control 
animals were culled.  
 
Figure 4.1 demonstrates serum urea and creatinine concentrations in all groups of 
animals, with significant differences observed between the uraemic and control 
groups at both day 3 and day 7.  
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Figure 4.1 Serum urea (A) and creatinine (B). Serum obtained from rats at time of 
culling at day 3 or day 7 demonstrated significant differences between control and 
uraemic groups in urea and creatinine. n = 5 per group. Data represented as median + 
95% CI analysed by Mann-Whitney U test; * denotes significance level p < 0.05 and 
** denotes p < 0.01. 
B 
A
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Figure 4.2 illustrates serum corticosterone concentrations as determined by ELISA 
(Bio-Techne). At day 3 and day 7 there was no significant difference between uraemic 
and control groups. There were no significant differences seen between the day 3 and 
day 7 control animals or between the day 3 and day 7 uraemic animals’ serum 
corticosterone concentrations.  
 
 
 
Figure 4.2 Serum corticosterone concentrations as determined by ELISA. Serum 
obtained from rats at time of culling demonstrated no difference between control and 
uraemic groups at day 3 or day 7, n = 5 per group. Data represented as median + 95% 
CI analysed by Kruskal-Wallis with Dunn’s multiple comparisons test. 
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With respect to the wounds themselves, uraemic animals showed a significant 
reduction in area of wounds healed compared to the control animals at day 7 (Figure 
4.3). This difference was not seen at day 3. In the control animals, healing was 
significantly greater at day 7 than day 3. Although this trend in area of wound healed 
being diminished was similar in uraemic animals from day 3 to day 7, this difference 
was not statistically significant (p = 0.065). 
 
  
 
Figure 4.3 Area of wound healed. Percentage area of wound healed as compared to 
wound made on day 0 was significantly greater in control versus uraemic groups at 
day 7.  n = 10 per group. Data represented as median + 95% CI analysed by Kruskal-
Wallis with Dunn’s multiple comparisons test. * denotes significance level p < 0.05. 
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From day 0 until the day of culling at day 7 the uraemic animals were noted to lose a 
significant amount of weight in contrast to the control animals that gained weight. 
There was no significant difference between the weights of the uraemic and control 
groups at day 3 (Figure 4.4). There were no significant differences between the day 3 
and day 7 control animal weights or the day 3 and day 7 uraemic animal weights.  
 
 
 
Figure 4.4 Percentage weight gain. Percentage weight gain as compared to day 0 
was significant in the control compared to the uraemic group culled at day 7. n = 5 
per group. Data represented as median + 95% CI analysed by Kruskal-Wallis with 
Dunn’s multiple comparisons test. * denotes significance level p < 0.05. 
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Skin corticosterone concentrations were determined after incubating a section of skin 
in DMEM (Sigma-Aldrich) without FBS or antibiotics overnight. The media was 
retrieved and utilized in an ELISA. These results were used as a surrogate marker of 
11β-HSD-1 activity. No differences were observed between control and uraemic 
animals’ skin corticosterone concentrations at day 3. Although the uraemic group of 
animals appeared to have greater corticosterone concentrations than their respective 
controls at day 7, these results did not achieve statistical significance (Figure 4.5). 
There were no significant differences between the day 3 and day 7 control animals’ 
skin corticosterone concentrations or the day 3 and day 7 uraemic animal skin 
corticosterone concentrations. 
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Figure 4.5 Skin corticosterone concentrations as determined by ELISA. After 
removal of subcutaneous fat and muscle, skin sections were incubated for 24 h in 1 
mL DMEM without FBS or antibiotics. Corticosterone concentrations assayed by 
ELISA from the media demonstrated no significant differences between control and 
uraemic groups at day 3 or 7. n = 5 per group. Data represented as median + 95% CI 
analysed by Kruskal-Wallis with Dunn’s multiple comparisons test.  
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Figure 4.6 Western blots of skin homogenates at day 3 post wounding. Protein 
bands from tissue homogenates were resolved by western blotting. Bands 
immunoreactive to antibodies for 11b-HSD-1 at 32 kDa, 11b-HSD-2 at 44 kDa and 
GAPDH at 36 kDa are shown. 
 
 
 
Figure 4.7 Western blots of skin homogenates at day 7 post wounding. Protein 
bands from tissue homogenates were resolved by western blotting. Bands 
immunoreactive to antibodies for 11b-HSD-1 at 32 kDa, 11b-HSD-2 at 44 kDa and 
GAPDH at 36 kDa are shown. 
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Skin samples from animals were homogenized to extract protein to be assessed by 
western blotting. Densitometry was performed using Image J software (version 
1.4.3.67) to semi-quantify the band density of 11b-HSD-1 or 11b-HSD-2 protein 
relative to GAPDH. A double band was seen at a lower molecular weight than 44 kDa 
on the western blot for 11b-HSD-2 at day 7. The most likely reason for this is due to 
sample degradation as homogenates were stored at -80oC, defrosted for protein 
quantification and frozen again at -20oC after preparation for western blotting. The 
length of time samples were frozen at both temperatures did vary, as did time to final 
use for western blotting. At day 3 and day 7, skin homogenates of the uraemic animals 
demonstrated more 11b-HSD-1 and 11b-HSD-2 protein expression compared to 
control animals although these results were not statistically significant (Figures 4.6, 
4.7 and 4.8).  
 
 
 
Figure 4.8 Densitometry; ratios of 11b-HSD-1 (A) and 11b-HSD-2 (B) relative to 
GAPDH. Performed on western blots of Figures 4.6 and 4.7. Data represented as 
median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple comparisons test.  
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4.2.2 Topical Emodin in Rat Wound Healing 
24 male Wistar rats were used for this experiment. 12 rats had uraemia induced by 
feeding a 0.75% adenine supplemented normal diet and the remaining 12 rats were 
fed normal chow and served as controls.  Each animal underwent wounding as 
described on day 0 (section 2.2.3.1).  Emodin was prepared in 2% Carbopol®934 
(Enzo Lifesciences) to form a gel that could be easily applied. On days 0 to 4, 0.5 mL 
of either emodin at 500 µg/mL or 1000 µg/mL was applied to each wound of 3 
uraemic and 3 control animals. Plain 2% Carbopol®934 (as the vehicle) was applied 
to each wound of 6 uraemic and 3 control animals. No treatment (henceforth denoted 
as ‘none’) was applied to 3 control animals (section 2.2.3.2). All animals were culled 
on day 7.  
 
Figure 4.9 demonstrates serum urea and creatinine concentrations in all 7 groups of 
animals. Differences observed between the uraemic and control groups did not reach 
statistical significance, likely due to small group sizes.  
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Figure 4.9 Serum urea (A) and creatinine (B). Serum obtained from rats at time of 
culling at day 7 demonstrated no statistically significant differences in urea and 
creatinine between control and uraemic groups with emodin 500 µg/mL, emodin 1000 
µg/mL or vehicle applied topically. n = 3 per group n = 6 per uraemic vehicle group. 
Data represented as median + 95% CI analysed by Mann-Whitney U test.  
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Figure 4.10 demonstrates serum corticosterone concentrations as determined by 
ELISA in each group, with no statistically significant results seen between control 
and uraemic groups for any treatment received. 
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Figure 4.10 Serum corticosterone concentrations as determined by ELISA. 
Serum obtained from rats at time of culling at day 7 demonstrated no significant 
difference between control and uraemic groups with vehicle, emodin 500 µg/mL or 
emodin 1000 µg/mL applied topically. n = 3 per group except n = 6 per uraemic 
vehicle group. Data represented as median + 95% CI analysed by Kruskal-Wallis with 
Dunn’s multiple comparisons test. 
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With respect to the wounds themselves, there was minimal difference in percentage 
area of wound healing between all control animal groups. Although not statistically 
significant, uraemic animals treated with vehicle did have wounds that healed less 
than either emodin treatment uraemic groups. There were no differences noted in 
healing between control and uraemic animals when either concentration of emodin 
was applied. Of note, there was still a statistically significant difference between the 
uraemic vehicle and control vehicle groups as well as between the uraemic vehicle 
and no treatment (none) group (Figure 4.11) demonstrating a delay in healing in 
uraemia at the baseline state.  
 
 
 
Figure 4.11 Area of wound healed. Percentage area of wound healed by day 7 as 
compared to wound made on day 0 was only significant between the control vehicle 
versus uraemic vehicle groups and the uraemic vehicle versus no treatment applied 
group. n = 6 per group except n = 12 uraemic vehicle group. Data represented as 
median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple comparisons test. 
* denotes significance level p < 0.05. 
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From day 0 to day 7 the uraemic animals were noted to lose weight in contrast to their 
respective control animals that gained weight. These differences were not statistically 
significant (Figure 4.12).  
 
Co
ntr
ol 
50
0
Ur
ae
mi
c 5
00
Co
ntr
ol 
10
00
Ur
ae
mi
c 1
00
0
Co
ntr
ol 
Ve
hic
le
Ur
ae
mi
c V
eh
icl
e
No
ne
-15
-10
-5
0
5
10
Pe
rc
en
ta
ge
 W
ei
gh
t G
ai
n 
(%
)
 
 
Figure 4.12 Percentage weight gain. Percentage weight gain as compared to day 0 
was not significant between control and uraemic groups with vehicle, emodin 500 
µg/mL or emodin 1000 µg/mL applied topically. n = 3 per group except n = 6 uraemic 
vehicle group. Data represented as median + 95% CI analysed by Kruskal-Wallis with 
Dunn’s multiple comparisons test. 
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Skin corticosterone concentrations were determined after incubating a section of skin 
in DMEM without FBS or antibiotics overnight (Figure 4.13). The media was 
retrieved and utilized by ELISA. No significant differences were found in 
corticosterone concentrations in the skin of uraemic animals treated with drug or 
vehicle compared to their respective control animals.  
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Figure 4.13 Skin corticosterone concentrations as determined by ELISA. After 
removal of subcutaneous fat and muscle, skin sections were incubated for 24 h in 1 
mL DMEM without FBS or antibiotics. Corticosterone concentrations assayed by 
ELISA from the media demonstrated no significant differences between control and 
uraemic groups with vehicle, emodin 500 µg/mL or emodin 1000 µg/mL applied 
topically. n = 3 per group except n = 6 per uraemic vehicle group. Data represented 
as median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple comparisons 
test. 
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Figure 4.14 Western blots of skin homogenates at day 7 post wounding, emodin 
500 µg/mL or vehicle administered. Protein bands from tissue homogenates were 
resolved by western blotting. Bands immunoreactive to antibodies for 11b-HSD-1 at 
32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. 
 
 
 
Figure 4.15 Western blots of skin homogenates at day 7 post wounding, emodin 
1000 µg/mL, vehicle or no treatment administered. Protein from tissue 
homogenates was resolved by western blotting. Bands immunoreactive to antibodies 
for 11b-HSD-1 at 32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. 
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Skin samples from animals were homogenized to extract protein to be assessed by 
western blotting.  Densitometry was performed using Image J software (version 
1.4.3.67) to semi-quantify the band intensity of 11b-HSD-1 or 11b-HSD-2 protein 
relative to GAPDH. In skin homogenates of animals treated with emodin at 500 
µg/mL or 1000 µg/mL there were no appreciable differences in 11b-HSD-1 or 11b-
HSD-2 protein expression when compared to respective controls by western blotting 
(Figure 4.14, 4.15 and 4.16). 
 
 
 
 
Figure 4.16 Densitometry; ratios of 11b-HSD-1 (A) and 11b-HSD-2 (B) relative 
to GAPDH. Performed on western blots of Figures 4.14 and 4.15. Data represented 
as median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple comparisons 
test. 
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4.2.3 Systemic Emodin in Rat Wound Healing at Day 3 
24 male Wistar rats were used for these experiments. 12 rats had uraemia induced by 
feeding a 0.75% adenine supplemented diet and the remaining 12 rats were fed normal 
chow and acted as controls.  Each animal underwent wounding as described on day 0 
(section 2.2.3.1). 12 uraemic and control animals received emodin 100 mg/kg by oral 
gavage on days 0 to 2, the remaining 12 uraemic and control animals received 10% 
ethanol (VWR International Ltd) as vehicle. All animals were culled on day 3 (section 
2.2.3.3). 
 
Figure 4.17 demonstrates serum urea and creatinine concentrations in all groups of 
animals, with significant differences found between the uraemic and control groups 
treated with drug and between the uraemic and control groups treated with vehicle.  
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Figure 4.17 Serum urea (A) and creatinine (B). Serum obtained from rats at time 
of culling at day 3 demonstrated significant differences in urea and creatinine between 
control and uraemic groups whether systemic emodin or vehicle was administered. n 
= 6 per group. Data represented as median + 95% CI analysed by Mann-Whitney U 
test; ** denotes significance level p < 0.01. 
 
 
A 
B 
 
 
121 
Figure 4.18 demonstrates serum corticosterone concentrations as determined by 
ELISA. Despite the control vehicle animals yielding an almost 2-fold greater serum 
corticosterone concentration than the uraemic vehicle treated animals, this difference 
did not achieve statistical significance (p = 0.110). There was no significant difference 
in serum corticosterone concentrations between either the control drug treated and 
uraemic drug treated animals (p > 0.999) nor between the 2 control groups or 2 
uraemic groups.  
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Figure 4.18 Serum corticosterone concentrations as determined by ELISA. 
Serum obtained from rats at time of culling at day 3 demonstrated no significant 
difference between the control and uraemic groups either with systemic emodin or 
vehicle administration. n = 6 per group. Data represented as median + 95% CI 
analysed by Kruskal-Wallis with Dunn’s multiple comparisons test. 
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With respect to the wounds themselves, uraemic drug treated animals demonstrated 
similar wound healing to control drug treated animals, with no significant difference 
observed between the percentage area of the wound healed (p > 0.999). However, this 
was also the case between the control vehicle treated and uraemic vehicle treated 
animals (p = 0.490) (Figure 4.19).  
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Figure 4.19 Area of wound healed. Percentage area of wound healed on day 3 as 
compared to wound made on day 0 was not significant between the control and 
uraemic groups with systemic emodin or vehicle administration. n = 12 per group. 
Data represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s 
multiple comparisons test. 
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From day 0 to day 3 the uraemic animals, irrespective of treatment received, had a 
lower weight in comparison to their respective control animals (not statistically 
significant) (Figure 4.20). In addition, the animals in each drug treated group had 
lower weights than their vehicle treated counterparts (not statistically significant). 
 
 
 
Figure 4.20 Percentage weight gain. Percentage weight gain as compared to day 0 
was not significant between control and uraemic groups with systemic emodin or 
vehicle administration in animals culled at day 3. n = 6 per group. Data represented 
as median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple comparisons 
test. 
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Skin corticosterone concentrations were determined after incubating a section of skin 
in DMEM without FBS or antibiotics overnight. The media was retrieved and utilized 
in the ELISA. The uraemic vehicle treated group had greater skin corticosterone 
concentrations compared to the uraemic emodin treated group (not statistically 
significant). In addition, the control vehicle treated group had greater skin 
corticosterone concentrations compared to the control emodin treated group although 
this did not reach statistical significance. There were no significant differences in 
corticosterone skin concentrations between the 2 drug treated groups or between the 
2 vehicle treated groups (Figure 4.21). The skin corticosterone concentrations seem 
to mirror the serum corticosterone concentrations measured.  
 
 
 
Figure 4.21 Skin corticosterone concentrations as determined by ELISA. After 
removal of subcutaneous fat and muscle, skin sections were incubated for 24 h in 1 
mL DMEM without FBS or antibiotics. Corticosterone concentrations assayed by 
ELISA from the media demonstrated no significant differences between control and 
uraemic groups with systemic emodin or vehicle administration. n = 6 per group. Data 
represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple 
comparisons test. 
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Figure 4.22 Western blots of skin homogenates at day 3 post wounding, emodin 
100 mg/kg systemically administered. Protein bands from tissue homogenates were 
resolved by western blotting. Bands immunoreactive to antibodies for 11b-HSD-1 at 
32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. 
 
 
 
Figure 4.23 Western blots of skin homogenates at day 3 post wounding, vehicle 
10% ethanol administered. Protein from tissue homogenates was resolved by 
western blotting. Bands immunoreactive to antibodies for 11b-HSD-1 at 32 kDa, 11b-
HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. 
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Skin samples from animals were homogenized to extract protein to be assessed by 
western blotting.  Densitometry was performed using Image J software (version 
1.4.3.67) to semi-quantify the amount of 11b-HSD-1 or 11b-HSD-2 protein relative 
to GAPDH. A double band was seen at a lower molecular weight than 32 kDa for 
some 11b-HSD-1 samples and lower than 36 kDa on all western blots for GAPDH, 
likely due to sample degradation. In skin homogenates of animals, uraemic or control, 
treated with emodin or vehicle there were no appreciable differences in 11b-HSD-1 
or 11b-HSD-2 protein expression by western blotting. (Figure 4.22, 4.23 and 4.24).  
 
 
 
Figure 4.24 Densitometry; ratios of 11b-HSD-1 (A) and 11b-HSD-2 (B) relative 
to GAPDH. Derived from day 3 post wounding western blots of Figures 4.22 and 
4.23. Data represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s 
multiple comparisons test. 
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4.2.4 Systemic Emodin in Rat Wound Healing at Day 7 
64 male Wistar rats were used for these experiments. 32 rats had uraemia induced by 
feeding a 0.75% adenine supplemented normal diet and the remaining 32 rats were 
fed normal chow and acted as controls. Each animal underwent wounding as 
described on day 0 (section 2.2.3.1). 16 uraemic and control animals received emodin 
100 mg/kg by oral gavage on days 0 to 4, the remaining 16 uraemic and control 
animals received 10% ethanol as vehicle. All animals were culled on day 7 (section 
2.2.3.3). 
 
Figure 4.25 demonstrates serum urea and creatinine concentrations in all groups of 
animals, with significant differences observed between the uraemic and control 
groups treated with drug and between the uraemic and control groups treated with 
vehicle.   
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Figure 4.25 Serum urea (A) and creatinine (B). Serum obtained from rats at time 
of culling at day 7 demonstrated significant differences between control and uraemic 
groups in urea and creatinine whether systemic emodin or vehicle was administered. 
n = 16 per group. Data represented as median + 95% CI analysed by Mann-Whitney 
U test; *** denotes significance level p < 0.001. 
 
A 
B 
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Figure 4.26 demonstrates serum corticosterone concentrations as determined by 
ELISA. There were no significant differences in serum corticosterone concentrations 
between either the control drug and uraemic drug treated animals or between the 
control vehicle and uraemic vehicle treated groups of animals.  
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Figure 4.26 Serum corticosterone concentrations as determined by ELISA. 
Serum obtained from rats at time of culling at day 7 demonstrated no significant 
difference between control and uraemic groups either with systemic emodin or 
vehicle administration. n = 16 per group. Data represented as median + 95% CI 
analysed by Kruskal-Wallis with Dunn’s multiple comparisons test. 
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With respect to the wounds themselves uraemic vehicle treated animals demonstrated 
significantly less wound healing compared to control vehicle treated animals as 
before. This difference disappeared under the influence of emodin, indicative of 
restoration of wound healing to the same extent as healthy controls. When comparing 
uraemic emodin treated animals with uraemic untreated animals a beneficial effect of 
emodin was clearly demonstrated. (Figure 4.27). This was not true when comparing 
healing in the control drug treated group with the control vehicle group, suggesting 
emodin has a predilection for working in the uraemic setting only possibly due to 
increased enzyme activity in uraemia. 
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Figure 4.27 Area of wound healed. Percentage area of wound healed on day 7 as 
compared to wound made on day 0 was significant between the uraemic drug and 
uraemic vehicle groups as well as between the control vehicle and uraemic vehicle 
groups n = 32 per group. Data represented as mean + 95% CI analysed by Kruskal-
Wallis with Dunn’s multiple comparisons test. * denotes significance level p < 0.05, 
*** denotes significance level p < 0.001. 
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From day 0 to day 7 the uraemic animals were noted to lose weight in contrast to the 
control animals that gained weight. The uraemic vehicle treated animals had a 
significant lower weight in comparison to the respective control vehicle treated 
animals (Figure 4.28). Although the uraemic drug treated animals had a lower weight 
than the control drug treated animals, this was not a statistically significant difference 
(p = 0.200).  
 
 
 
Figure 4.28 Percentage weight gain. Percentage weight gain as compared to day 0 
was significant in the control versus uraemic groups treated with vehicle. n = 16 per 
group. Data represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s 
multiple comparisons test. *** denotes significance level p < 0.001. 
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Skin corticosterone concentrations were determined after incubating a section of skin 
in DMEM without FBS or antibiotics overnight. The media was retrieved and utilized 
in the ELISA. The uraemic emodin treated group had lower skin corticosterone 
concentrations compared to the uraemic vehicle treated group, although this result 
was not statistically significant. In addition, the control vehicle treated group had 
lower skin corticosterone concentrations compared to the uraemic vehicle treated 
group although this also did not reach statistical significance (Figure 4.29). 
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Figure 4.29 Skin corticosterone concentrations as determined by ELISA. After 
removal of subcutaneous fat and muscle, skin sections were incubated for 24 h in 1 
mL DMEM without FBS or antibiotics. Corticosterone concentrations assayed by 
ELISA from the media demonstrated no significant differences between control and 
uraemic groups whether systemic emodin or vehicle was administered. n = 16 per 
group. Data represented as median + 95% CI analysed by Kruskal-Wallis with Dunn’s 
multiple comparisons test. 
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Figure 4.30 Representative western blots of skin homogenates at day 7 post 
wounding, emodin 100mg/kg systemically administered. Protein bands from tissue 
homogenates were resolved by western blotting. Bands immunoreactive to antibodies 
for 11b-HSD-1 at 32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. 
Blot representative of total n = 16 per group. 
 
 
 
Figure 4.31 Representative western blots of skin homogenates at day 7 post 
wounding, vehicle 10% ethanol administered. Protein from tissue homogenates 
was resolved by western blotting. Bands immunoreactive to antibodies for 11b-HSD-
1 at 32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. Blot 
representative of total n = 16 per group.  
  
Control             Adenine
GAPDH
GAPDH
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Skin samples from animals were homogenized to extract protein to be assessed by 
western blotting.  Densitometry was performed using Image J software (version 
1.4.3.67) to semi-quantify the band density of 11b-HSD-1 or 11b-HSD-2 protein 
relative to GAPDH. (Double bands seen at a lower than expected molecular weight 
are likely due to sample degradation). In skin homogenates of animals treated with 
emodin there was greater 11b-HSD-1 protein expression than vehicle treated 
counterparts. This was applicable for uraemic as well as control animals, although the 
results were not statistically significant. No significant differences in 11b-HSD-2 
protein expression were found (Figure 4.30, 4.31 and 4.32).  
 
 
 
Figure 4.32 Densitometry; ratios of 11b-HSD-1 (A) and 11b-HSD-2 (B) relative 
to GAPDH. Performed on all western blots from skin homogenates at day 7 post 
wounding including Figures 4.30 and 4.31. Data represented as median + 95% CI 
analysed by Kruskal-Wallis with Dunn’s multiple comparisons test. 
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4.2.4.1 The Effect of Systemic 11b-HSD-1 Inhibition on Liver 
 
 
 
Figure 4.33 Western blots of liver homogenates at day 7 post wounding, emodin 
100 mg/kg systemically administered. Protein bands from tissue homogenates were 
resolved by western blotting. Bands immunoreactive to antibodies for 11b-HSD-1 at 
32 kDa, 11b-HSD-2 at 44 kDa and GAPDH at 36 kDa are shown. 
 
 
 
Figure 4.34 Western blots of liver homogenates at day 7 post wounding, vehicle 
10% ethanol administered. Protein from tissue homogenates was resolved by 
western blotting. Bands immunoreactive to antibodies for 11b-HSD-1 at 32 kDa, 11b-
HSD-2 at 44 kDa and GAPDH at 36 kDa are shown.  
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Densitometry was performed using Image J software (version 1.4.3.67) to semi-
quantify the band density of 11b-HSD-1 or 11b-HSD-2 protein relative to GAPDH. 
In liver homogenates of animals treated with emodin there was greater 11b-HSD-1 
protein expression than vehicle treated animals. This was applicable for uraemic as 
well as control animals, although the results were not statistically significant. There 
were no significant differences in 11b-HSD-2 protein expression (Figure 4.33, 4.34 
and 4.35). These results parallel the 1b-HSD-1 and 11b-HSD-2 protein expression 
results seen for skin homogenates (Figure 4.32). 
 
 
 
Figure 4.35 Densitometry; ratios of 11b-HSD-1 (A) and 11b-HSD-2 (B) relative 
to GAPDH. Performed on western blots of Figures 4.33 and 4.34 Data represented 
as median + 95% CI analysed by Kruskal-Wallis with Dunn’s multiple comparisons 
test. 
 
 
4.2.5 Summary of in vivo Results 
In all experiments, the concentrations of serum urea and creatinine were consistently 
greater in the uraemic compared to the control groups. Statistically the results were 
not significant in the topical emodin experiment, even though serum results were 
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comparable to other experiments. This is likely due to the small numbers of animals 
per group rather than failure in the induction of experimental uraemia per se. 
 
Serum corticosterone concentrations were not statistically significantly different 
between uraemic and control groups at day 3 or day 7 whether no treatment, topical 
or systemic emodin or the corresponding vehicle only was administered.  
 
When measuring skin corticosterone concentrations by ELISA, no statistically 
significant results were obtained in any experiment. In animals administered systemic 
emodin and culled at day 3, there was a trend towards greater skin corticosterone 
concentrations in vehicle treated rather than emodin treated animals (whether they 
were control or uraemic animals), which was not seen at day 7 after systemic emodin 
administration.  
 
From the initial wound healing experiment, it was evident that uraemic animals healed 
less well compared to control animals at day 7. Predictably, more healing was evident 
at day 7 compared to day 3 in both uraemic and control groups although this was only 
statistically significant for the control groups. This suggests the rate of healing is 
delayed in uraemic rats. In the topical emodin experiment, significantly reduced 
percentage of area of wound healed in the uraemic vehicle treated group compared to 
control vehicle or no treatment groups was demonstrated in keeping with the baseline 
experiment. No differences in healing were found between the topical emodin treated 
control and uraemic animals, suggesting that topical emodin improves healing in 
uraemic animals to a similar extent of healing in control emodin treated animals. It is 
prudent to treat this result with caution as the apparent effect may simply be due to 
small group numbers. When systemic emodin was administered, no differences in 
wound healing were demonstrated at day 3. However, by day 7, significantly less 
healing was seen in the uraemic vehicle treated group compared to the control vehicle 
treated group in keeping with previous findings of delayed healing in uraemia. 
Conversely, percentage wound healing was similar in the control and uraemic emodin 
treated groups suggesting systemic emodin in uraemic animals improves wound 
healing to that of control emodin treated animals. In support of this, significantly more 
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healing was noted in the uraemic emodin treated group compared to the uraemic 
vehicle treated group but not between the two control groups.  
 
The significant differences in wound healing between uraemic and control animals 
treated with emodin at day 7 do not correlate with changes in serum or skin 
corticosterone concentrations, suggesting that either the methods employed here are 
not suitably designed to measure changes in 11b-HSD-1 activity or that alternate 
pathways are implicated in poor wound healing in uraemia. As systemic emodin 
treatment seems to improve healing in uraemic animals to the same degree as control 
animals, more studies should be performed to define the mechanism of action of 
emodin in the uraemic state. Delineating the pharmacokinetics and 
pharmacodynamics of emodin and comparing this within other organs, in both the 
uraemic and non uraemic state would be informative. Studying other specific 11b-
HSD-1 inhibitors would also add strength to the use of such drugs in aiding wound 
healing in future. 
 
Due to the small numbers of animals in each group, with considerable variability in 
weights it is difficult to draw firm conclusions about animal weights across all 4 in 
vivo experiments.  In initial experiments at day 3, control and uraemic animals lost 
weight to a similar extent. At day 3, after systemic emodin or vehicle administration 
no statistically significant differences in animal weight were established. In initial 
experiments at day 7, control animals gained significantly more weight than uraemic 
animals that lost weight. This pattern remained significant in animals culled at day 7 
after systemic vehicle administration. Although a similar pattern was noted for the 
animals treated with systemic emodin in the same experiment this result did not attain 
statistical significance. A similar trend was seen in the topical emodin experiment, 
with uraemic animals losing weight and control animals gaining weight irrespective 
of treatment, although these results were not statistically significantly different. 
Animals could not be caged individually due to spatial logistics in the biological 
services unit. Although each cage had a plentiful supply of drinking water and feed, 
it is likely each cage had more dominant animals that influenced feeding within the 
group. To tease out whether weight has a direct impact on wound healing would 
require more detailed studies into mass of chow consumed per single caged animal as 
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well as further measurements such as trans-epidermal water loss of skin and tensile 
strength. 
 
11b-HSD-1 protein expression appeared greater in uraemic animals than control 
animals at day 3 and day 7 of the baseline experiment, although this did not attain 
statistical significance. Robust conclusions cannot be drawn about 11b-HSD-1 
protein expression after topical emodin or vehicle administration due to the small 
sample sizes (n = 3) used. Furthermore, the rats were found to have removed the 
dressings applied after wounding and topical emodin or vehicle administration during 
vigorous grooming. It was not possible to ensure each animal received the proposed 
topical dose as a result, or to exclude accidental systemic dosing after licking their 
wounds. To ensure the dressings remained intact, the animals would have to be 
subjected to prolonged general anaesthesia or the dressings sutured in situ which 
would be impractical for repeated dosing, not to mention beyond the remit of our 
Home Office project license. 
 
After 3 days of systemic emodin or vehicle administration, no differences in 11b-
HSD-1 expression were observed. At day 7, although both control and uraemic 
emodin treated animals’ skin appeared to express more 11b-HSD-1 than their vehicle 
counterparts this was not statistically significant when densitometry was performed. 
No significant differences in 11b-HSD-1 expression were seen between the drug 
treated animals or between the vehicle treated animals either. Likewise, 11b-HSD-1 
expression in liver homogenates mimicked this pattern with no significant differences 
found between the drug treated animals or between the vehicle treated animals but 
both control and uraemic emodin treated animals’ liver again appeared to express 
more 11b-HSD-1 than their vehicle counterparts (not statistically significant by 
densitometry).  
 
With regards to 11b-HSD-2 protein expression from skin homogenates, it appeared 
as though greater 11b-HSD-2 protein expression was observed at both day 3 and day 
7 in uraemic animals compared to their respective controls (not statistically 
significant). No significant differences were demonstrated in the experiments 
utilizing topical or systemic emodin although a trend to increased 11b-HSD-2 protein 
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expression was observed in the uraemic vehicle treated animals compared to the 
control vehicle treated animals in the systemic emodin experiments. No significant 
differences in 11b-HSD-2 protein expression were observed in western blots of liver 
homogenates from the systemic emodin experiment. 
 
4.2.6 PCR 
4.2.6.1 Reverse Transcription PCR for 11b-HSD-1 and B2M 
Skin samples from 24 of the male Wistar rats of experiment described in section 
2.2.3.3 were used for these experiments. 12 rats had uraemia induced by feeding a 
0.75% adenine supplemented normal diet and the remaining 12 rats were fed normal 
chow and acted as controls.  Each animal underwent wounding as described (section 
2.2.3.1) on day 0. 6 uraemic and control animals received emodin 100 mg/kg by oral 
gavage on days 0 to 4, the remaining 6 uraemic and control animals received 10% 
ethanol as vehicle. All animals were culled on day 7. 
 
Skin samples were initially snap frozen in liquid nitrogen and stored at -80oC until 
ready for use. These samples were homogenized in a ceramic pestle and mortar with 
liquid nitrogen until a powder was formed, then transferred to a RNase free Eppendorf 
(Fisher Scientific Ltd). After addition of 300 µL Buffer RLT (Qiagen) they were 
stored at -80oC until ready to extract RNA utilizing the RNeasy® Fibrous Tissue Mini 
Kit (Qiagen). 
 
The samples were analysed with a Nanodrop (Thermo Scientific Nanodrop 2000c 
Spectrophotometer) for RNA quantity and integrity. An A260/A280 ratio of 2.0 was 
accepted as being sufficiently pure to proceed with further experimentation. A260/A230 
ratios were also analysed for additional information regarding RNA contamination. 
An A260/A230 in the range of 2.0-2.2 is ordinarily the aim. 21 of the 24 RNA samples 
had A260/A280 ratios of greater than 2.0. The remaining 3 samples had ratios above 1.9 
so were still utilized for further experiments with caution (Table 4.1). All 24 samples 
had very low A260/A230 ratios, this may be due to a contaminant absorbing at 230nm 
or less which has been seen in guanidine contamination (175) (used in column based 
kits such as the RNeasy® Fibrous Tissue Mini Kit). 
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After reverse transcription, all samples were run in the PCR reaction with TaqMan® 
probes for 11b-HSD-1, 11b-HSD-2 and B2M (described in 2.5.4 from Thermo Fisher 
Scientific). To calculate CT values, the threshold was manually set to be the same 
across all runs within the Rotor-Gene Q software. CT values of sample replicates were 
excluded if > 0.3 CT difference was noted and samples were then run again in a 
subsequent PCR reaction. Inbuilt analysis via the 2-standard curve method was 
employed to obtain relative gene expression for each sample.  
 
Despite multiple attempts with 2 different TaqMan® probes for 11b-HSD-2, 
reproducible results could not be obtained for half the samples and hence further 
analysis did not proceed. These inaccuracies were also noted for the DNA standards 
used with these probes (data not shown). 
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Sample ID ng/ µL A260 A280 A260/A280 A260/A230 
1 27.3 0.682 0.318 2.14 0.51 
2 7.1 0.178 0.069 2.57 0.12 
3 38.0 0.950 0.477 *1.99 1.24 
4 4.2 0.105 0.042 2.53 0.48 
5 17.8 0.445 0.209 2.13 1.67 
6 33.2 0.829 0.387 2.14 1.08 
7 30.8 0.770 0.371 2.08 0.64 
8 10.9 0.272 0.117 2.33 0.06 
9 39.6 0.990 0.478 2.07 1.39 
10 11.7 0.291 0.125 2.33 0.58 
11 36.2 0.906 0.432 2.10 0.33 
12 19.6 0.491 0.234 2.10 1.82 
13 105.7 2.642 1.293 2.04 0.76 
14 83.1 2.079 1.025 2.03 0.73 
15 26.6 0.666 0.325 2.05 0.78 
16 83.3 2.084 1.021 2.04 1.19 
17 48.2 1.206 0.581 2.07 1.35 
18 101.7 2.543 1.242 2.05 1.56 
19 63.6 1.589 0.819 *1.94 0.59 
20 61.2 1.531 0.756 2.03 0.80 
21 11.7 0.292 0.151 *1.93 0.10 
22 26.2 0.654 0.319 2.05 0.54 
23 48.8 1.220 0.572 2.13 1.17 
24 39.6 0.990 0.490 2.02 0.51 
 
Table 4.1 Nanodrop results for RNA extracted from skin samples.  
* denotes A260/A280 ratios under 2.0.  
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Figure 4.36 Representative amplification curves of gene of interest 11b-HSD-1. 
 
 
 
Figure 4.37 Representative amplification curves of housekeeping gene B2M. 
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Figure 4.38 Representative standard curve from PCR analysis. Standard curve 
replicates demonstrated in blue, unknown samples and No Template Controls 
demonstrated in red. 
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Sample 11b-HSD-1 
Concentration ng/µL 
B2M Concentration 
ng/µL 
Relative 
Concentration 
1 0.0028 0.7216 0.0040 
2 0.0055 0.5418 0.0090 
3 0.0005 0.1111 0.0040 
4 0.0001 0.0475 0.0030 
5 0.0650 0.7100 0.1040 
6 0.0696 0.6568 0.1200 
7 0.0121 0.4168 0.0260 
8 0.0030 0.2714 0.0100 
9 0.0030 0.2838 0.0100 
10 0.0242 0.3670 0.0750 
11 0.0268 0.2101 0.1450 
12 0.0194 0.2831 0.0780 
13 0.0040 0.1928 0.0190 
14 0.0214 0.6388 0.0330 
15 0.0650 0.2288 0.3230 
16 0.1071 0.1246 0.9780 
17 0.0123 0.9699 0.0120 
18 0.0155 0.5487 0.0280 
19 0.0062 0.3319 0.0170 
20 0.0052 0.4256 0.0110 
21 0.0074 0.1969 0.0370 
22 0.0298 0.0200 1.6950 
23 0.0177 0.6067 0.0290 
24 0.0066 0.3573 0.0180 
 
Table 4.2 11b-HSD-1 Expression Relative to B2M expression. 
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Figure 4.39 Relative expression of 11b-HSD-1 normalised to B2M.  n= 6 per group. 
Data represented as median + 95% CI, analysed by Kruskal Wallis with Dunn’s 
multiple comparison test. 
 
 
No significant differences in 11b-HSD-1 mRNA expression were noted between the 
drug treated groups or the vehicle treated groups. In addition, there were no significant 
differences noted between each uraemic group and its respective control (Figure 
4.39). 
 
4.2.6.2 Wound Healing PCR Array 
12 of the RNA samples extracted to use for PCR were also reverse transcribed using 
the RT2 First Strand Kit for use in a Rat Wound Healing PCR Array (both Qiagen). 
This commercially available array is ready prepared with primer assays for 84 wound 
healing focused genes and 5 housekeeping genes as well as PCR controls. Using one 
RNA sample per array, the expression of key genes involved in all aspects of the 
wound healing response can be acquired. This profile can then be compared across 
differing experimental conditions to ascertain those genes with altered expression 
under said conditions. In these experiments, 3 samples were utilised per treatment 
group; control emodin treated, uraemic emodin treated, control vehicle treated and 
uraemic vehicle treated. 
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4.2.6.2.1 Quality Control PCR Array 
All 12 cDNA samples were first run in a Quality Control array (Qiagen) to ensure 
they were suitable for use in further experiments. Reverse transcription controls are 
included to check for impurities in the RNA sample that can affect the reverse 
transcription step of the array, whereas the Positive PCR control checks for impurities 
in the sample that could inhibit the PCR amplification of the positive PCR control and 
hence also the mRNA of interest. The Genomic DNA control is included to ascertain 
whether the sample has been contaminated with genomic DNA. The No Reverse 
Transcription Control is an additional control to assess the amount of DNA 
contamination in the sample as the reverse transcriptase enzyme is absent. Finally, a 
No Template Control does not contain DNA or RNA template, hence serves as a 
control for any nucleic acid contamination. The pass/fail considerations and results 
obtained are demonstrated in Table 4.3 and 4.4 respectively. The 12 chosen samples 
fulfilled all the necessary requirements to proceed 
 
 Pass Fail 
Reverse Transcription 
Control (RTC) 
CT 25 to 36 – CT 73 to 84 
value < 5 
CT 25 to 36 – CT 73 to 84 
value > 5 
Positive PCR Control 
(PPC) 
CT 37 to 48 – CT 73 to 84 < 3 CT 37 to 48 – CT 73 to 84 > 3 
Genomic DNA 
Contamination 
Control (GDC) 
CT 49 – 60 > 33 CT 49 – 60 < 33 
No Reverse 
Transcription Control 
(NRT) 
CT 61 to 72 value ³ 33 or 
NA 
CT 61 to 72 value < 33 or 
NA 
No Template Control 
(NTC) 
CT 85 to 96 value ³33 or 
NA 
CT 85 to 96 value < 33 or 
NA 
 
Table 4.3 Quality control parameters to ascertain whether RNA samples are 
suitable to proceed with further experimentation. 
Numbers in superscript denote well position on RotorDisc-100. Adapted from Qiagen 
(151) 
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Sample RTC PPC GDC NRT NTC 
1 2.57 0.26 > 35 36.26 > 35 
2 2.69 0.39 > 35 > 35 > 35 
3 2.30 0.35 > 35 > 35 > 35 
4 2.06 0.31 > 35 > 35 > 35 
5 2.03 0.31 35.76 > 35 > 35 
6 2.20 0.33 > 35 > 35 > 35 
7 3.03 0.50 > 35 > 35 > 35 
8 2.75 0.41 33.48 > 35 > 35 
9 2.12 0.13 36.97 38.36 > 35 
10 2.51 0.44 > 35 > 35 > 35 
11 2.91 0.27 > 35 > 35 > 35 
12 2.36 0.26 34.48 34.6 > 35 
 
Table 4.4 Quality control PCR array results for RNA samples. 
 
 
4.2.6.2.2 Rat Wound Healing PCR Array 
Each RNA sample was run in a separate Rat Wound Healing PCR array Rotor-disc 
100 ring (Qiagen) under identical run conditions to obtain CT values per gene of 
interest. The CT values were collated in one Microsoft Excel file and analysed using 
Qiagen’s data analysis centre. The following volcano plots were obtained for the data 
analysed. 
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Figure 4.40 Volcano plot for gene expression when comparing uraemic vehicle 
treated animals with control vehicle treated animals. This plot displays statistical 
significance of p < 0.05 (y-axis) against fold change of 2 (x-axis). Genes above the 
horizontal black line are statistically significant as per the Student’s t-test. 
 
Genes Over 
Expressed 
Fold Change p Value 
Itga5 4.21 0.0186 
 
Table 4.5  Genes over expressed with greater 2 fold difference when  comparing 
uraemic vehicle treated animals with control vehicle treated animals. 
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Figure 4.41 Volcano plot for gene expression when comparing control emodin 
treated animals with control vehicle treated animals. This plot displays statistical 
significance of p < 0.05 (y-axis) against fold change of 2 (x-axis).  Genes above the 
horizontal black line are statistically significant as per the Student’s t-test. 
 
Genes Over 
Expressed 
Fold Change p Value 
Cxcl3 17.78 0.0203 
Col4a1 11.07 0.0239 
Wnt5a 8.55 0.0209 
 
Table 4.6 Genes over expressed with greater than 2 fold difference when 
comparing control emodin treated animals with control vehicle treated animals. 
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Figure 4.42 Volcano plot for gene expression when comparing uraemic emodin 
treated animals with uraemic vehicle treated animals. This plot displays statistical 
significance of p < 0.05 (y-axis) against fold change of 2 (x-axis). Genes above the 
horizontal black line are statistically significant as per the Student’s t-test. 
 
Genes Under 
Expressed 
Fold Change p Value 
Plat -37.87 0.0090 
Itga5 -4.24 0.0134 
 
Table 4.7 Genes under expressed with greater than 2 fold difference when 
comparing uraemic emodin treated animals with uraemic vehicle treated 
animals. 
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4.2.6.2.3 Interpretation of Wound Healing Arrays 
4.2.6.2.3.1 The Effect of Uraemia on Wound Healing Related Gene Transcription 
When comparing uraemic vehicle treated versus control vehicle treated groups, 
infererences can be made with regards to wound healing gene transcription that could 
be altered by the uraemic state. Only one gene showed a greater than 2 fold difference 
in expression with a significance of p < 0.005. (See appendix for gene expression that 
may be altered but did not reach statistical significance). 
 
Itga5 was expressed 4.21 fold greater in uraemic animals than control animals (p = 
0.0186). The integrin family of heterodimeric transmembrane receptors are important 
in mediating cell attachments to extracellular matrix molecules and adjacent cells. 
They are composed of an alpha chain and a beta chain (176). Integrin 5 alpha is one 
such protein which undergoes post-translational cleavage, binding with a beta 1 chain 
to form a fibronectin receptor. During wound healing, migrating keratinocytes at the 
leading edge of the wound have been shown to express a5b1 thought to allow 
keratinocyte attachment and migration over the wound matrix (177, 178). Integrins 
also have a role in cell-surface mediated signalling (176). 
 
4.2.6.2.3.2 The Effect of Emodin on Wound Healing Related Gene Transcription 
in Control Animals 
When comparing control emodin treated versus control vehicle treated groups, 
inferences can be made with regards to wound healing gene transcription that could 
be mediated by emodin. Three genes showed a greater than 2 fold difference in 
expression with a significance of p < 0.005. (See appendix for gene expression that 
may be altered but did not reach statistical significance). 
 
Cxcl3 was expressed 17.78 fold greater in emodin treated control animals than control 
vehicle treated animals (p = 0.0203). Chemokines are chemoattractive proteins 
implicated in cell to cell communication as well as directing migration of structural 
cells (179). Chemokine ligand 3 is a cytokine involved in the acute inflammatory 
response. It has a role in recruiting and activating polymorphonuclear leukocytes as 
well as bearing pro angiogenic properties (180). 
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Col4a1 was expressed 11.07 fold greater in emodin treated control animals  than 
control vehicle treated animals (p = 0.0239). Collagen type IV alpha 1 is a subunit of 
type IV collagen, a major structural component of  the BM (181). The non collagenous 
domain or NC1 domain has been shown to possess antiangiogenic properties in vivo. 
NCI binds to a1b1 integrin, inhibiting signalling pathways in vascular epithelial cells 
(182). It has also been found to regulate HIF-1a and VEGF by inhibiting the Mitogen-
Activated Protein Kinases (MAPK)  signaling cascade (182, 183). 
 
Wnt5a was expressed 8.55 fold greater in emodin treated control animals than control 
vehicle treated animals (p = 0.0209). Wnts are lipid modified secreted glycoproteins 
that have roles in the regulation of development, cell proliferation and differentiation 
(184). Wnt5a has been shown to have an important role in hair follicle morphogenesis 
(185). In addition, it is expressed in human primary endothelial cells as well as murine 
vasculature and has been shown to promote angiogenesis, induce endothelial cell 
proliferation and enhance cell survival. Wnt5a expression has also been shown to 
enhance capillary network formation (186). 
 
4.2.6.2.3.3 The Effect of Emodin on Wound Healing Related Gene Transcription 
in Uraemic Animals 
When comparing uraemic emodin treated versus uraemic vehicle treated groups, 
inferences can be made with regards to wound healing gene transcription that could 
be mediated by emodin but altered by the uraemic state. Two genes showed a greater 
than 2 fold difference in expression with a significance of p < 0.005. (See appendix 
for gene expression that may be altered but did not reach statistical significance). 
 
Plat was expressed 37.87 fold less in uraemic emodin treated animals compared to 
uraemic vehicle treated animals (p = 0.009). Tissue plasminogen activator is a serine 
protease found on endothelial cells and histiocytes (187). It catalyzes the conversion 
of plasminogen to plasmin. Plasmin is an enzyme involved in the break down of blood 
clots (188, 189). Studies have shown wound closure is delayed in plasminogen 
deficient mice (190). Sulnite et al. demonstrated plasminogen transport to the wound 
by inflammatory cells and that in plasminogen deficient mice, excess fibrin and 
neutrophil deposition was observed in the wound after re-epethelialisation had 
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occurred, representing chronic inflammation. They postulated that fibroblast function 
was impaired in the absence of plasminogen contributing to a delay in granulation 
tissue formation. Hence, as well as being an activator of the inflammatory phase of 
healing, plasminogen is also required to terminate the inflammatory phase 
appropriately (191). 
 
Itga5 was expressed 4.24 fold less in uraemic emodin treated animals compared to 
uraemic vehicle treated animals (p = 0.0134). Intrestingly this was downregulated 
with emodin treatment in uraemia where as the gene was significantly upregulated in 
uraemic vehicle animals compared to control vehicle treated animals (section 
4.2.6.2.3.1). 
 
4.2.7 Histology 
Wounds and surrounding skin sections obtained as 24 animals were culled on day 7 
after either emodin or vehicle administration (see section 2.2.3.3 and 2.2.4) were 
excised, bisected, mounted on PVDF membrane (Fisher Scientific Ltd) and placed in 
10% neutral buffered formalin solution (Sigma-Aldrich). A small portion of the liver 
was retrieved to use as a positive control. After 24 hours, these were transferred and 
stored in 70% ethanol (VWR International Ltd) before processing by Ismail Bulut at 
Barts Health NHS Trust. After paraffin embedding, sections obtained were stained 
with haematoxylin and eosin (not shown), 11b-HSD-1 (Aviva Systems Biology) and 
Picro-sirius red (Sigma-Aldrich) (Figures 4.43. 4.44 and 4.45). 
 
Professor Sheaff at Barts Health NHS Trust, who was blinded to the animals’ 
treatment groups, reviewed all slides, allocating each animal a weighted score based 
on the intensity of 11b-HSD-1 staining in the sections. Figure 4.46 demonstrates the 
median score by each treatment group. No significant differences were noted between 
the drug treated groups or the vehicle treated groups. There were also no significant 
differences in the intensity of 11b-HSD-1 staining between the two control groups or 
between the two uraemic groups. 11b-HSD-1 was reported to be present in 
keratinocytes, fibroblasts, endothelial cells as well as inflammatory cells, with no 
predominance for a single cell type. Additionally, 11b-HSD-1 staining was observed 
in subcutaneous muscle as expected. 
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Picro-sirius red staining was performed as a difference in collagen presence in 
uraemic versus control animals could be pertinent in wound healing. Although formal 
histological analysis has not yet been performed, there appears to be no difference in 
distribution or density of collagen whether the sections are from uraemic animals or 
drug treated animals. 
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Figure 4.43 Immunohistochemistry for 11b-HSD-1 on representative skin 
sections. 40X magnification. A) control vehicle treated, B) control drug treated, C) 
uraemic drug treated and D) uraemic vehicle treated (C & D overleaf). Wounds and 
surrounding skin retrieved from rats at time of culling at day 7 after systemic emodin 
or vehicle administration.  
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Figure 4.44 Immunohistochemistry for 11b-HSD-1 on representative skin 
sections. A) magnification 100X B) magnification 250X. 
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Figure 4.45 Immunohistochemistry for Picro-sirius red on representative skin 
sections. A) control vehicle treated, B) control drug treated, C) uraemic drug treated 
and D) uraemic vehicle treated (C & D overleaf). Wounds and surrounding skin 
retrieved from rats at time of culling at day 7 after systemic emodin or vehicle 
administration. Scale demonstrated on figure. 
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Figure 4.46 11b-HSD-1 intensity score. Intensity of immunohistochemical staining 
for 11b-HSD-1 on skin sections was assessed by a Consultant Histopathologist in a 
blinded fashion. No significance difference was reported between groups irrespective 
of whether systemic emodin or vehicle was administered. n = 12 wounds per group. 
Data represented as median + 95% CI, analysed by Kruskal Wallis with Dunn’s 
multiple comparison test. 
 
 
4.3 Discussion 
11b-HSD-1 is a bidirectional enzyme. Although oxoreductase activity has previously 
been shown to predominate in intact cells such as fibroblasts (80) (converting 11-
dehydrocorticosterone to corticosterone in rodents), the directionality is unstable and 
dependent on the availability of NADPH, which in turn is reliant on H6PDH presence 
in high enough concentrations in the ER lumen (80-82). The enzyme is under complex 
regulatory control by many factors such as GC and stress (70, 80) which could only 
be controlled for in a limited way in experiments of this kind (same culture media, 
dark conditions in an incubator set at 37oC). Although skin samples were snap frozen 
in liquid nitrogen upon retrieval and stored at -80oC until ready for use, samples had 
to be defrosted to remove subcutaneous fat and weigh prior to incubation. Every effort 
was made to keep the samples on ice as much as possible, however, the effect freeze-
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thawing may have had on enzyme activity is unknown. Ideally, both potential 
products of 11b-HSD-1 activity (11-dehydrocorticosterone and corticosterone) would 
have been measured on the media samples to determine the ratio of oxoreductase to 
dehydrogenase activity present, although it would be difficult to remove 11b-HSD-2 
activity from this equation (catalyzes corticosterone to 11-dehydrocorticosterone). 
The optimal method to measure 11b-HSD-1 activity would be using isotopically 
labelled cortisol (192) which was unavailable to my laboratory group during the study 
period. 
 
Although an ex vivo model of wound healing has been previously described by 
Stojadinovic et al. (98, 193), as has the determination of steroid concentrations from 
cell culture media (55), a combination of the two methods as used in this study has 
seldom been employed.  Corticosterone concentrations obtained from experiments 
were within the range detectable by the assay (0.1 - 25 ng/mL) (194), but the 
conditions of the experiment such as 24-hour period of incubation of skin in the 
culture medium, volume of media per skin sample, composition of media may not 
have been fully optimized to measure peak skin corticosterone concentrations. 
 
Many difficulties were encountered in processing skin samples to obtain sufficient 
total protein for western blotting and good quality and quantity RNA for PCR 
reactions. Various methods of homogenisation were attempted including using 
different lysis buffers, a BeadBugTM microtube homogenizer (Sigma-Aldrich) with 
changeable sized microbeads, the Cryo-Cup Grinder consisting of a double-walled 
insulating cup within which a stainless-steel mortar is embedded and a pestle made of 
a non-heat conductive plastic (Stratech Scientific Ltd, Cambridgeshire, UK), the 
Silent Crusher S Homogenizer (Type 5F) (Heidolph, Essex, UK) and a Micro Cryo 
Crusher (Stratech Scientific Ltd). Ultimately, manual homogenization using a rough 
coated ceramic pestle and mortar prevailed as the most effective method of skin 
breakdown to a fine powder. Plentiful liquid nitrogen was required to keep the system 
cool throughout as well as perseverance and acceptance each sample would take time 
and considerable arm strength. 
 
 
 
163 
Western blotting is a useful method for determining the presence or absence of a 
protein of interest, however no information can be ascertained as to whether the 
protein detected is physiologically active. Additionally, preliminary experiments are 
needed to optimize protein concentrations used in electrophoresis as well as primary 
and secondary antibody concentrations used in the detection phase. Unfortunately, 
once these conditions had been optimized the manufacturer of the antibodies used 
(Santa Cruz Biotechnology) had its research license revoked under the Animal 
Welfare Act due to allegations of mistreatment of goats and rabbits. Although it was 
still possible to purchase these antibodies commercially from other sources until 
stocks were exhausted, I considered this ethically questionable. Antibodies from an 
alternative producer (Aviva Systems Biology) were hence obtained and optimized for 
use in all experiments. 
 
When quantifying 11b-HSD-1 mRNA expression in skin samples after 7 days of 
emodin or vehicle administration, no significant differences were noted between the 
4 treatment groups. It may be that this time point is too late to observe differences as 
Tiganescu et al. noted early differences (at day 2) when examining wound healing in 
mice (94). It is important to appreciate that our study design differed from their 
experiments in that the rodents they used were female, hairless mice. Additionally, 
control skin used was unwounded skin obtained from the lower dorsal region of the 
same animals in contrast to data presented in this chapter. If skin including the 
wounded area had been used for western blots and PCR reactions, different results 
may have been obtained. Unfortunately, PCR for 11b-HSD-2 mRNA was 
unsuccessful despite multiple attempts using 2 different TaqMan® probes for 11b-
HSD-2. Tiganescu et al. found 11b-HSD-2 mRNA expression was negligible in mice 
(92), it is possible that the rat specific probes used here were not able to give consistent 
results for a similar reason. As discussed with regards to western blotting, mRNA 
expression of a protein that is a bidirectional enzyme, does not enlighten us as to 
physiologically active consequences and thus has limited value in isolation. 
 
The results of the wound healing array should also be interpreted with caution due to 
small group sizes (n = 3). Skin homogenates were used as source of RNA for the 
arrays, yield of RNA was reasonably low and high CT values were obtained. The 
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online data analysis site advises interpreting these figures with caution, although a 
greater or less than 2-fold change may have been recorded, they cannot be validated 
without a reasonable number of biological replicates (See Appendix 7.3, 7.4 and 7.5 
for full list of up and downregulated genes with explanations of why caution is 
required). It would be interesting to compare arrays performed on serum samples for 
the same animals and to increase each group’s sample size. 
 
We aspired to measure granulation tissue areas from skin sections to quantify healing. 
However, it became evident when mounting and sectioning samples that 
incorporating the centre of the wound was not possible (on tissue retrieval wounds 
were bisected possibly disrupting granulation tissue that had formed). It was 
reportedly difficult to ensure sections were cut in a plane exactly parallel to this 
meaning the wound area would not be consistently represented across samples. 
 
The results obtained from the experiments within this chapter do consistently 
demonstrate reduced wound healing in uraemic rats when compared to control 
animals at 7 days. This effect was independent of serum or skin corticosterone 
concentrations and cannot be solely attributed to weight loss associated with the 
uraemic state. With the administration of systemic emodin, by day 7 wound healing 
in uraemic animals was seen to improve to the same level as non-uraemic animals 
also receiving the drug. No significant differences were reported in either 11b-HSD-
1 or 11b-HSD-2 mRNA or protein expression using the methods employed. This was 
as predicted, as enzyme inhibition would not necessarily cause protein synthesis to be 
upregulated.  
 
A positive control for the in vivo experiments (a compound known to promote wound 
healing specifically in uraemia), to my knowledge is not currently available. This 
could have been useful to evaluate the size of effect of emodin against. The use of 
additional known 11b-HSD-1 inhibitors such as R0151 (93) was precluded by 
accessibility and cost, although this inhibitor like others is yet to be studied in CKD. 
 
The shortfalls of this study include the inability to measure 11b-HSD-1 activity 
reliably by the more sensitive and reproducible radioactive isotope assay to establish 
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the role of 11b-HSD-1 in wound healing. Additionally, such an assay will help in 
teasing out emodin induced 11b-HSD-1 inhibition or other pleotropic effects in 
wound healing. Comparing the effects of other 11b-HSD-1 specific inhibitors (in 
development for dementia and hypertension) would further substantiate a putative 
role of 11b-HSD-1 in wound healing. For definitive evidence a skin specific 11b-
HSD-1 KO could be utilized. However, experiments conducted thus far would need 
to be repeated in a mouse model to ensure consistent results were obtained prior to 
using a KO model. Interestingly, translation of this experimental research could be 
relatively simple (after ethical approval) as human skin is readily accessible intra-
operatively. 
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CHAPTER 5 
Final Discussion  
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In this thesis, I have found that both 11b-HSD-1 and 11b-HSD-2 are present in HEK 
and HDF cell lysates (detected by western blotting). In response to treatment with the 
uraemic toxins IS and PC in isolation, 11b-HSD-1 and 11b-HSD-2 continued to be 
expressed, with no differences seen when compared to cells with no toxin exposure. 
HEK and HDF cells treated with the selective 11b-HSD-1 inhibitor emodin, 
unsurprisingly continued to express 11b-HSD-1 and 11b-HSD-2, again with no 
differences noted when compared to untreated cells. I established an in vitro wound 
healing scratch assay with and without solitary uraemic toxin exposure but did not 
demonstrate significant differences in healing with IS, PC or emodin. Despite the ease 
and reproducibility of this model, it cannot be used in the uraemic setting as it is likely 
many potential uraemic toxins play a role in combination rather than in isolation. 
Additionally, monolayer cell cultures do not provide a true to life environment to 
study the complex cell-cell or cell-extracellular matrix interactions involved in wound 
healing. 
 
I aimed to determine the activity of 11b-HSD-1 in skin in uraemia which proved to 
be challenging with the techniques available in our laboratory. An indirect method of 
measuring enzyme activity was employed which measured the product of 11b-HSD-
1 activity (cortisol in human cells and corticosterone for rodent samples). In vitro, 
upon addition of IS, PC or emodin the concentration of cortisol produced by HDF 
cells was too low to be detected. In HEK cells, cortisol concentrations were 
quantifiable but no differences in production were determined in the simulated 
uraemic environment or when cells were treated with emodin. 
 
My in vivo studies confirmed the presence of 11b-HSD-1 and 11b-HSD-2 in the skin 
of uraemic as well as non-uraemic control Wistar rats. I have consistently 
demonstrated that rats have delayed wound healing in experimental uraemia. As 
expected there was no difference in the expression of both isoforms of 11b-HSD by 
western blotting in skin homogenates. I detected 11b-HSD-1 mRNA in equivalent 
quantities in uraemic and control rats although technical difficulties were encountered 
when assessing 11b-HSD-2 mRNA expression. Immunohistochemical analysis by a 
Consultant Histopathologist blinded to treatment groups corroborated the presence of 
11b-HSD-1 in fibroblasts, keratinocytes and endothelial cells in the skin of both 
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uraemic and control animals with no clear differences in enzyme expression noted. I 
established an ELISA technique to measure corticosterone concentrations using skin 
samples ex vivo to indirectly assess 11b-HSD-1 activity but unfortunately this was 
not sensitive enough to delineate small changes in corticosterone production. I did not 
have access to a hot lab using radioactive isotope techniques in my institute during 
my studies to reliably measure 11b-HSD-1 activity. 
 
Despite these difficulties, I could demonstrate that the 11b-HSD-1 inhibitor emodin 
administered systemically can restore wound healing in experimental uraemia. 
Although I encountered problems in the practicalities of topical emodin use in rats, I 
consider it still has potential to be used via the topical route, either as a cream or as 
embedded dressings in the clinical setting. 
 
The work described in this thesis is a small step in addressing a deficit in the published 
literature regarding the important but neglected field of wound healing in patients 
with established renal failure. Delayed wound healing is associated with significant 
morbidity and mortality in uraemic patients. There is an urgent need to find novel 
therapies to promote speedy wound healing and I believe the work presented here 
provides the foundation for avenues to be pursued in future.  
 
To confirm a role for 11b-HSD-1 in wound healing in uraemia, methods that can 
directly measure the enzyme activity and directionality should be pursued. Tiganescu 
et al. did demonstrate acceleration of wound healing with an inhibitor of 11b-HSD-1 
(RO151) as well as by using a 11b-HSD-1 global KO mouse (93). The use of an 11b-
HSD-1 skin specific KO could be employed to help validate such results in a uraemic 
mouse model designed to study wound healing. 
 
It would be interesting to explore the mechanism of action of emodin in the uraemic 
state further. Emodin has previously been shown to improve wound healing after 
topical administration in non-uraemic rats (107). The authors suggested a TGF-b1 
mediated upregulation of Smad 2/Smad 3 and downregulation of Smad 7 related gene 
transcription could be involved. However, in the work presented here, healing in 
emodin treated uraemic animals improved to equal that of emodin treated non-
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uraemic animals at day 7. Why the beneficial actions of emodin would seem to prefer 
uraemic conditions thus far remains unanswered. 
 
To assist further studies in wound healing in end stage renal failure, the wound healing 
array utilised in these studies could be used as a starting point. By analysing the serum 
of uraemic animals versus non uraemic animals (with larger group sizes) to elucidate 
which genes are upregulated or down regulated, which phase of wound healing is 
affected and potential biological pathways implicated, the net would be cast wide in 
the search for key effectors. Comparison to arrays run with RNA derived from skin 
samples could assist in narrowing down the search to a tissue specific level. 
Subsequent experiments could then be planned to substantiate these findings. 
 
The field could be further expanded by studying healing across the 5 stages of chronic 
kidney disease, as well as in patients treated with haemodialysis, peritoneal dialysis 
or renal transplantation. Diabetes mellitus is a leading cause of CKD in the UK. Many 
patients suffer considerable morbidity owing to the combined effects of their diabetes 
and renal failure. An important clinical manifestation of this is the poor wound healing 
seen in diabetic foot ulcers, often leading to devastating limb amputations. It would 
be valuable to design a diabetic uraemic wound healing model to study factors 
implicated in poor healing as well as to develop therapeutic agents that could be used 
in the clinical setting to overcome these. The beneficial effects of 11b-HSD-1 
inhibition attenuating insulin resistance in addition to my observations of improved 
wound healing makes this pathway an ideal candidate for future translational research. 
I would recommend that human skin from uraemic and non uraemic donors with and 
without diabetes be used to study differences in 11b-HSD-1 activity with the 
subsequent administration of topical therapies to verify restoration of wound healing. 
 
The current standard of care in renal transplant recipients and patients afflicted with 
autoimmune conditions with kidney involvement such as the ANCA-associated 
vasculitides and lupus nephritis has included large doses of systemic glucocorticoids 
which are associated with a multitude of complications including delayed wound 
healing. Morgan et al. demonstrated that the reactivation of GCs by 11b-HSD-1 in 
peripheral tissues (rather than circulating levels) is a key contributor to the Cushingoid 
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phenotype of GC excess in mice. Moreover, the side effects associated with GC 
excess such as glucose intolerance, hepatic steatosis, adiposity, hypertension, 
myopathy and dermal atrophy were ameliorated in global 11b-HSD-1 KO mice (41). 
Considering this information, 11b-HSD-1 inhibition, either topically or systemically 
to mitigate the side effects of exogenously administered steroids in skin and other 
organs could prove highly beneficial. 
 
The work described in this thesis demonstrates some of the complexities of studying 
wound healing in renal impairment. Nonetheless, poor healing remains an important 
clinical issue with scope for intervention to minimise complications and reduce 
morbidity and mortality. Finding targets such as 11b-HSD-1 (inhibition of which 
would be safe as KO mice do not exhibit any adverse phenotype) that could be 
inhibited with inexpensive drugs would be greatly welcomed. 
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7.2 Gene Table from RT2 Profiler PCR Array- Rotor Disc 100 Format 
 
 
Array layout
The 96 real-time assays in the Rotor-Gene format are located in wells 1–96 of the Rotor-Disc™ (plate
A1–A12=Rotor-Disc 1–12, plate B1–B12=Rotor-Disc 13–24, etc.). To maintain data analysis
compatibility, wells 97–100 do not contain real-time assays but will contain master mix to account
for weight balance.
Gene table: RT² Profiler PCR Array
Position UniGene GenBank Symbol Description
A01 Rn.195319 NM_031004 Acta2 Smooth muscle alpha-actin
A02 Rn.3114 NM_019183 Actc1 Actin, alpha, cardiac muscle 1
A03 Rn.161953 NM_053546 Angpt1 Angiopoietin 1
A04 Rn.137780 NM_001105822 Ccl12 Chemokine (C-C motif) ligand 12
A05 Rn.26815 NM_001007612 Ccl7 Chemokine (C-C motif) ligand 7
A06 Rn.44218 NM_053353 Cd40lg CD40 ligand
A07 Rn.1303 NM_031334 Cdh1 Cadherin 1
A08 Rn.99441 NM_001130548 Col14a1 Collagen, type XIV, alpha 1
A09 Rn.2953 NM_053304 Col1a1 Collagen, type I, alpha 1
A10 Rn.107239 NM_053356 Col1a2 Collagen, type I, alpha 2
A11 Rn.3247 NM_032085 Col3a1 Collagen, type III, alpha 1
A12 Rn.53801 NM_001135009 Col4a1 Collagen, type IV, alpha 1
B01 Rn.121139 NM_001135759 Col4a3 Collagen, type IV, alpha 3
B02 Rn.117 NM_134452 Col5a1 Collagen, type V, alpha 1
B03 Rn.2875 NM_053488 Col5a2 Collagen, type V, alpha 2
B04 Rn.38654 NM_021760 Col5a3 Collagen, type V, alpha 3
B05 Rn.44285 XM_340799 Csf2 Colony stimulating factor 2 (granulocyte-macrophage)
B06 Rn.53973 NM_017104 Csf3 Colony stimulating factor 3 (granulocyte)
B07 Rn.17145 NM_022266 Ctgf Connective tissue growth factor
B08 Rn.112601 NM_053357 Ctnnb1 Catenin (cadherin associated protein), beta 1
B09 Rn.103332 NM_001106041 Ctsg Cathepsin G
B10 Rn.5598 NM_031560 Ctsk Cathepsin K
B11 Rn.1294 NM_013156 Ctsl1 Cathepsin L1
B12 Rn.10907 NM_030845 Cxcl1 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)
C01 Rn.13664 NM_182952 Cxcl11 Chemokine (C-X-C motif) ligand 11
C02 Rn.10525 NM_138522 Cxcl3 Chemokine (C-X-C motif) ligand 3
C03 Rn.44449 NM_022214 Cxcl5 Chemokine (C-X-C motif) ligand 5
C04 Rn.6075 NM_012842 Egf Epidermal growth factor
C05 Rn.37227 NM_031507 Egfr Epidermal growth factor receptor
C06 Rn.42925 NM_021698 F13a1 Coagulation factor XIII, A1 polypeptide
C07 Rn.9980 NM_013057 F3 Coagulation factor III (thromboplastin, tissue factor)
C08 Rn.98846 NM_001008724 Fga Fibrinogen alpha chain
C09 Rn.44439 NM_012951 Fgf10 Fibroblast growth factor 10
C10 Rn.31808 NM_019305 Fgf2 Fibroblast growth factor 2
C11 Rn.98842 NM_022182 Fgf7 Fibroblast growth factor 7
C12 Rn.10148 NM_012945 Hbegf Heparin-binding EGF-like growth factor
D01 Rn.10468 NM_017017 Hgf Hepatocyte growth factor
D02 Rn.10795 NM_138880 Ifng Interferon gamma
D03 Rn.6282 NM_178866 Igf1 Insulin-like growth factor 1
D04 Rn.9868 NM_012854 Il10 Interleukin 10
D05 Rn.9869 NM_031512 Il1b Interleukin 1 beta
D06 Rn.9871 NM_053836 Il2 Interleukin 2
D07 Rn.108255 NM_201270 Il4 Interleukin 4
D08 Rn.9873 NM_012589 Il6 Interleukin 6
D09 Rn.12138 NM_001008725 Il6st Interleukin 6 signal transducer
D10 Rn.91044 NM_030994 Itga1 Integrin, alpha 1
D11 Rn.83597 XM_345156 Itga2 Integrin, alpha 2
D12 Rn.154664 NM_001108292 Itga3 Integrin, alpha 3
E01 Rn.12704 NM_001107737 Itga4 Integrin, alpha 4
E02 Rn.100796 NM_001108118 Itga5 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide)
E03 Rn.161799 XM_215984 Itga6 Integrin, alpha 6
E04 Rn.23339 NM_001106549 Itgav Integrin, alpha V
E05 Rn.25733 NM_017022 Itgb1 Integrin, beta 1
E06 Rn.162202 NM_153720 Itgb3 Integrin, beta 3
E07 Rn.16988 NM_147139 Itgb5 Integrin, beta 5
E08 Rn.19828 NM_001004263 Itgb6 Integrin, beta 6
E09 Rn.34914 NM_053842 Mapk1 Mitogen activated protein kinase 1
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Position UniGene GenBank Symbol Description
E10 Rn.2592 NM_017347 Mapk3 Mitogen activated protein kinase 3
E11 Rn.2661 NM_031051 Mif Macrophage migration inhibitory factor
E12 Rn.79007 NM_001134530 Mmp1a Matrix metallopeptidase 1a (interstitial collagenase)
F01 Rn.6422 NM_031054 Mmp2 Matrix metallopeptidase 2
F02 Rn.10282 NM_012864 Mmp7 Matrix metallopeptidase 7
F03 Rn.10209 NM_031055 Mmp9 Matrix metallopeptidase 9
F04 Rn.10999 NM_012801 Pdgfa Platelet-derived growth factor alpha polypeptide
F05 Rn.107102 NM_013151 Plat Plasminogen activator, tissue
F06 Rn.6064 NM_013085 Plau Plasminogen activator, urokinase
F07 Rn.82711 NM_017350 Plaur Plasminogen activator, urokinase receptor
F08 Rn.20178 NM_053491 Plg Plasminogen
F09 Rn.22158 NM_031606 Pten Phosphatase and tensin homolog
F10 Rn.44369 NM_017232 Ptgs2 Prostaglandin-endoperoxide synthase 2
F11 Rn.29157 NM_134366 Rac1 Ras-related C3 botulinum toxin substrate 1
F12 Rn.107401 NM_057132 Rhoa Ras homolog gene family, member A
G01 Rn.29367 NM_012620 Serpine1
Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type
1), member 1
G02 Rn.10247 NM_012747 Stat3 Signal transducer and activator of transcription 3
G03 Rn.34397 NM_031549 Tagln Transgelin
G04 Rn.9952 NM_012671 Tgfa Transforming growth factor alpha
G05 Rn.40136 NM_021578 Tgfb1 Transforming growth factor, beta 1
G06 Rn.9953 NM_017256 Tgfbr3 Transforming growth factor, beta receptor III
G07 Rn.25754 NM_053819 Timp1 TIMP metallopeptidase inhibitor 1
G08 Rn.2275 NM_012675 Tnf Tumor necrosis factor (TNF superfamily, member 2)
G09 Rn.1923 NM_031836 Vegfa Vascular endothelial growth factor A
G10 Rn.87493 NM_019156 Vtn Vitronectin
G11 Rn.63486 NM_031716 Wisp1 WNT1 inducible signaling pathway protein 1
G12 Rn.48749 NM_022631 Wnt5a Wingless-type MMTV integration site family, member 5A
H01 Rn.94978 NM_031144 Actb Actin, beta
H02 Rn.1868 NM_012512 B2m Beta-2 microglobulin
H03 Rn.47 NM_012583 Hprt1 Hypoxanthine phosphoribosyltransferase 1
H04 Rn.107896 NM_017025 Ldha Lactate dehydrogenase A
H05 Rn.973 NM_001007604 Rplp1 Ribosomal protein, large, P1
H06 N/A U26919 RGDC Rat Genomic DNA Contamination
H07 N/A SA_00104 RTC Reverse Transcription Control
H08 N/A SA_00104 RTC Reverse Transcription Control
H09 N/A SA_00104 RTC Reverse Transcription Control
H10 N/A SA_00103 PPC Positive PCR Control
H11 N/A SA_00103 PPC Positive PCR Control
H12 N/A SA_00103 PPC Positive PCR Control
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7.3 Control Drug versus Control Vehicle Array Gene Expression 
 
 
 
  
Genes Over-Expressed in Group 1 vs. Control Group
Position Gene Symbol Fold Regulation Comments RT2 Catalog
E03 Itga6 56.46 B PPR47334G
G01 Serpine1 56.20 B PPR48309B
E06 Itgb3 28.43 B PPR46423E
C02 Cxcl3 17.78  PPR06598A
F06 Plau 11.36 B PPR43507F
A12 Col4a1 11.07  PPR50699A
G10 Vtn 9.98 B PPR52673A
G12 Wnt5a 8.55  PPR50278A
F01 Mmp2 5.58 B PPR43605D
E01 Itga4 4.96 B PPR55836A
B02 Col5a1 4.91 B PPR42270A
F07 Plaur 4.86 B PPR52384B
F08 Plg 4.42 B PPR46984A
C12 Hbegf 3.94 B PPR44696B
D09 Il6st 3.38 B PPR06402E
B09 Ctsg 3.29 B PPR55085A
D05 Il1b 3.11 B PPR06480B
G05 Tgfb1 2.92 B PPR06430B
A08 Col14a1 2.86 B PPR53940A
B04 Col5a3 2.46 B PPR49105A
A09 Col1a1 2.46 A PPR42922A
A01 Acta2 2.39 A PPR59337B
B10 Ctsk 2.31 B PPR43443A
G03 Tagln 2.28 A PPR48695F
C05 Egfr 2.26 B PPR48960A
A06 Cd40lg 2.26 B PPR49715A
H01 Actb 2.20  PPR06570C
G04 Tgfa 2.13 B PPR06486A
C10 Fgf2 2.05 B PPR06641B
13
Genes Under-Expressed in Group 1 vs. Control Group
Position Gene Symbol Fold Regulation Comments RT2 Catalog
F02 Mmp7 -6.43 B PPR44767C
H06 RGDC -4.73 B
C06 F13a1 -4.54 B PPR49546A
C03 Cxcl6 -4.41 B PPR06441B
D01 Hgf -3.25 B PPR44869B
A04 Ccl12 -2.89 B PPR52425A
D07 Il4 -2.84 B PPR56680A
C08 Fga -2.31 B PPR53691F
H10 PPC -2.26  
H12 PPC -2.19  
H11 PPC -2.13  
G11 Wisp1 -2.05 C PPR51404A
A05 Ccl7 -2.05 C PPR06685B
B06 Csf3 -2.05 C PPR50733A
B05 Csf2 -2.05 C PPR49732A
D06 Il2 -2.05 C PPR06481A
C04 Egf -2.02 B PPR43509B
14
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7.4 Uraemic Drug versus Uraemic Vehicle Array Gene Expression 
 
 
Genes Over-Expressed in Group 3 vs. Group 2
Position Gene Symbol Fold Regulation Comments RT2 Catalog
D04 Il10 25.70 B PPR06479A
F07 Plaur 14.03 B PPR52384B
C08 Fga 9.56 B PPR53691F
F08 Plg 9.54 B PPR46984A
E12 Mmp1 8.34 B PPR52149A
E06 Itgb3 8.08 B PPR46423E
A05 Ccl7 8.06 B PPR06685B
F03 Mmp9 7.47 B PPR44728C
G10 Vtn 7.40 B PPR52673A
F06 Plau 5.62 B PPR43507F
C12 Hbegf 5.37 B PPR44696B
C10 Fgf2 4.28 B PPR06641B
G12 Wnt5a 4.17 B PPR50278A
A09 Col1a1 3.72 B PPR42922A
C03 Cxcl6 3.50 B PPR06441B
B01 Col4a3 3.43 B PPR53065A
E01 Itga4 3.40 B PPR55836A
F01 Mmp2 3.23 B PPR43605D
D07 Il4 2.47 C PPR56680A
F02 Mmp7 2.47 C PPR44767C
A04 Ccl12 2.47 C PPR52425A
D08 Il6 2.47 C PPR06483B
A06 Cd40lg 2.47 C PPR49715A
D06 Il2 2.47 C PPR06481A
C09 Fgf10 2.47 C PPR06632A
B06 Csf3 2.47 C PPR50733A
B09 Ctsg 2.47 C PPR55085A
B05 Csf2 2.47 C PPR49732A
B04 Col5a3 2.47 C PPR49105A
G08 Tnf 2.47 C PPR06411F
D01 Hgf 2.47 C PPR44869B
F10 Ptgs2 2.33 B PPR49747F
H11 PPC 2.24  
D02 Ifng 2.24 B PPR45050C
H10 PPC 2.20  
B10 Ctsk 2.17 B PPR43443A
H12 PPC 2.14  
A02 Actc1 2.02 B PPR42970F
19
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7.5 Uraemic Vehicle versus Control Vehicle Array Gene Expression 
 
 
 
 
 
Genes Under-Expressed in Group 3 vs. Group 2
Position Gene Symbol Fold Regulation Comments RT2 Catalog
F05 Plat -37.87  PPR56502A
G07 Timp1 -11.98 B PPR48051C
A12 Col4a1 -9.32 B PPR50699A
G01 Serpine1 -6.71 B PPR48309B
F04 Pdgfa -5.98 B PPR06694C
D11 Itga2 -5.38 B PPR52451A
A07 Cdh1 -4.70 B PPR42461A
G06 Tgfbr3 -4.48 B PPR06487A
C02 Cxcl3 -4.41 B PPR06598A
E02 Itga5 -4.24  PPR54377A
D05 Il1b -4.10 B PPR06480B
E04 Itgav -3.77 B PPR47575B
B02 Col5a1 -2.85 B PPR42270A
E08 Itgb6 -2.75 B PPR46909A
D03 Igf1 -2.58 B PPR06664F
G03 Tagln -2.00 B PPR48695F
20
Genes Over-Expressed in Group 2 vs. Control Group
Position Gene Symbol Fold Regulation Comments RT2 Catalog
E03 Itga6 21.20 B PPR47334G
G01 Serpine1 16.41 B PPR48309B
C02 Cxcl3 10.77 B PPR06598A
D05 Il1b 5.23 B PPR06480B
B02 Col5a1 4.68 B PPR42270A
A12 Col4a1 4.47 B PPR50699A
E02 Itga5 4.21  PPR54377A
E01 Itga4 3.91 B PPR55836A
A03 Angpt1 3.71 B PPR57511C
C04 Egf 3.55 B PPR43509B
C11 Fgf7 2.80 B PPR06649A
F07 Plaur 2.54 B PPR52384B
G11 Wisp1 2.39 B PPR51404A
16
Genes Under-Expressed in Group 2 vs. Control Group
Position Gene Symbol Fold Regulation Comments RT2 Catalog
C06 F13a1 -21.86 B PPR49546A
B04 Col5a3 -11.58 B PPR49105A
D12 Itga3 -6.98 B PPR44350A
G12 Wnt5a -4.65 B PPR50278A
C08 Fga -4.13 B PPR53691F
A09 Col1a1 -3.77 B PPR42922A
A04 Ccl12 -3.54 B PPR52425A
B10 Ctsk -3.34 B PPR43443A
G08 Tnf -3.30 B PPR06411F
D08 Il6 -3.26 B PPR06483B
F02 Mmp7 -3.17 B PPR44767C
C10 Fgf2 -2.82 B PPR06641B
H06 RGDC -2.67 B
D01 Hgf -2.62 B PPR44869B
17
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7.6 Wound Healing Array Key 
 
A: This gene’s average threshold cycle is relatively high (> 30) in either the 
control or the test sample, and is reasonably low in the other sample (< 30). These 
data mean that the gene’s expression is relatively low in one sample and 
reasonably detected in the other sample suggesting that the actual fold-change 
value is at least as large as the calculated and reported fold-change result. This 
fold-change result may also have greater variations if p value > 0.05; therefore, it 
is important to have a sufficient number of biological replicates to validate the 
result for this gene. 
 
B: This gene’s average threshold cycle is relatively high (> 30), meaning that its 
relative expression level is low, in both control and test samples, and the p-value for 
the fold-change is either unavailable or relatively high (p > 0.05). This fold-change 
result may also have greater variations; therefore, it is important to have a sufficient 
number of biological replicates to validate the result for this gene. 
 
C: This gene’s average threshold cycle is either not determined or greater than the 
defined cut-off (default 35), in both samples meaning that its expression was 
undetected, making this fold-change result erroneous and un-interpretable. 
